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Abbrevations 
5FU    5 Fluorouracil  
CAF    Cancer-associated fibroblast 
CD8   Cluster of differentiation 8 
CD10    Cluster of differentiation 10 
CFC    Capillary filtration coefficient 
COPC    Capillary colloid osmotic pressure 
COPIF   Interstitial colloid osmotic pressure 
CK14   Cytokeratin 14 
CXCL5  CXC motif chemokine ligand 5 
DCIS   Ductal carcinoma in situ 
ECM    Extracellular matrix 
EMT    Epithelial-to-mesenchymal transition 
ER    Estrogen receptor 
FAP    Fibroblast activation protein 
FFPE   Formalin-fixed, paraffin-embedded 
FGF   Fibroblast growth factor 
FSP-1   Fibroblast specific protein-1 
GPR77  G protein-coupled receptor 77 
HER2    Human epidermal growth factor receptor 2 
HGF   Hepatocyte growth factor 
HNSCC  Head and neck squamous cell carcinoma 
iCAF   Inflammatory cancer-associated fibroblast 
IF   Interstitial fluid 
IHC   Immunohistochemistry 
IGF1    Insulin-like growth factor 1 
IGF2   Insulin-like growth factor 2 
Jv    Filtration 
KO mice   Knockout mice 
LOX   Lysyl oxidase 
LOXL1  Lysyl oxidase like 1 
METABRIC  Molecular taxonomy of breast cancer international consortium 
MMP   Matrix metalloproteinases 
MMTV  Mouse mammary tumor virus  
mRNA   Messenger ribonucleic acid 
myCAF  Myofibroblastic cancer-associated fibroblast 
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NG2   Neuron glial antigen 2 
PAM50  Prediction Analysis of Microarray 50 
Pc    Capillary hydrostatic pressure 
PDAC   Pancreatic ductal adenocarcinoma 
PDGF   Platelet-derived growth factor 
PDGFRα   Platelet-derived growth factor receptor alpha 
PDGFRβ   Platelet-derived growth factor receptor beta 
PIF    Interstitial fluid pressure 
PR    Progesterone receptor 
PyMT   Polyomavirus middle T antigen 
RNA   Ribonucleic acid 
SCID   Severe combined immunodeficiency disease 
SI   Staining index 
TNM   Tumor-nodes-metastasis 
TME   Tumor microenvironment 
TNBC   Triple-negative breast cancer 
TGF-β   Transforming growth factor beta 
VEGF   Vascular endothelial growth factor 
WT    Wild type 
α11-KO   Integrin α11 knockout 
αSMA   Alpha smooth muscle actin 
σ    Colloid osmotic reflection coefficient 
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Abstract 
Breast cancer cells are strongly influenced by a complex tumor microenvironment 
comprised of a diversity of stromal cells, including a heterogeneous population of cancer-
associated fibroblasts (CAFs), in addition to the extracellular matrix and the interstitial fluid 
with its solutes. Integrins act as links between the extracellular matrix and the cell 
cytoskeleton, and integrin α11β1 had previously been shown to be important for fibroblast 
function in wound healing, fibrosis and in lung cancer. In this thesis, we aimed to achieve 
a better understanding of the expression and functions of integrin α11β1 in the breast tumor 
microenvironment.  
In the first two papers we explored the effects of stromal integrin α11β1 in triple-negative 
breast cancer in integrin α11 knockout mice and demonstrated that integrin α11-deficiency 
reduced tumor interstitial fluid pressure and altered collagen fibril structure in MDA-MB-
231 and MDA-MB-468 tumors. In addition, integrin α11-deficiency reduced MDA-MB-
231 growth and the same trend was seen in MDA-MB-468 tumors. However, no effects of 
integrin α11β1 were seen in 4T1 tumors except altered collagen fibril structure. In the third 
paper, we validated new monoclonal antibodies against the human integrin α11 chain and 
established conditions for reproducible staining on formalin-fixed, paraffin-embedded 
(FFPE) human tissues. By investigating the expression of integrin α11 with the 210F4B6A4 
monoclonal antibody in a large breast cancer cohort, we reported that integrin α11β1 is 
expressed in fibroblast-like, stromal cells in the vast majority of invasive breast carcinoma. 
Strong integrin α11β1 expression was associated with aggressive breast cancer features, 
although not with breast cancer specific survival. Further, integrin α11β1 co-localized with 
αSMA in fibroblast-like cells, and αSMA and cytokeratin 14 in a subset of breast 
myoepithelium.  
In summary, this thesis has uncovered a new function of integrin α11β1 in the regulation 
of tumor interstitial fluid pressure in experimental breast cancer. Integrin α11β1 stimulated 
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MDA-MB-231 growth in vivo and was associated with aggressive cancer phenotypes in 
human breast cancer, indicating that integrin α11β1 seems to be expressed in a pro-
tumorigenic CAF subset. We also detected integrin α11β1 in a subset of breast 
myoepithelial cells, and the function in these cells is so far not known. Our new monoclonal 
antibodies against the integrin α11 chain represent new tools for use in further investigation 
of the expression and function of integrin α11β1. 
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1. Introduction 
1.1 Tumor microenvironment 
Cancer remains one of the leading causes of death worldwide despite extensive research in 
the field, and it surpassed cardiovascular disease as the leading cause of death in Norway 
in 2017 [1,2]. It is characterized by abnormal cell growth and ability to spread, and cells 
acquire a malignant phenotype through accumulation of mutations and epigenetic 
alterations [3,4].  
Hanahan and Weinberg proposed ten essential capabilities acquired during the multistep 
process of cancer development as seen in Fig 1 [3,4]. Although genetic alterations in the 
cancer cells, such as activation of oncogenes and inactivation of tumor suppressor genes, 
are necessary for the acquisition of the hallmark traits, cancer is a complex structure where 
tumor cells are embedded in an intricate tumor microenvironment (TME) [5,6]. Even 
though the microenvironment in solid carcinomas mainly consists of the same components 
as the microenvironment in normal tissue, it can be markedly altered.  
 
Fig 1. Hallmarks of cancer.  A. Hanahan and Weinberg proposed six hallmark capabilities of cancer in 
2000. B. In 2011, two extra hallmarks and two characteristics that facilitate acquisition of the hallmarks 
were added. Reprinted from [3], with permission. 
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Indeed, tumor cells remodel the TME into a milieu supportive of their own growth, and in 
this way, both cellular and non-cellular components of the TME can contribute to the 
acquisition of the hallmark traits – increasing the complexity of malignant tumors [5,6].  
A better understanding of the complex interplay between the tumor cells and the 
surrounding TME can hopefully result in more effective cancer treatment. Recent advances 
in immunotherapy certainly demonstrate that targeting the TME can be a powerful tool in 
the treatment of cancer. Nonetheless, components of the TME often have multiple and 
complex functions where some components even have been shown to restrain tumor growth 
and, with the exception of immunotherapy, targeting the TME in clinical trials has so far 
not been very successful [7-9]. This underlines the importance of comprehensive 
knowledge of the different parts of the TME through thorough and broad preclinical and 
translational research. 
The TME has been the framework of the research presented in this thesis; and in particular 
the role and expression of integrin α11β1 in the breast cancer stroma. Different 
compartments of the TME will be addressed in the following sections, with special focus 
on cancer-associated fibroblasts (CAFs), extracellular matrix (ECM), interstitial fluid (IF), 
and also integrins, particularly integrin α11β1. 
 
Fig 2. The tumor microenvironment. The tumor cells are embedded in a complex microenvironment. 
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1.1.1 Cells of the tumor microenvironment 
The TME is composed of a variety of non-malignant cells, including CAFs, a 
heterogeneous population of immune cells, vascular and lymphatic endothelial cells, blood 
vessel associated smooth muscle cells, pericytes, adipocytes, nerve cells and mesenchymal 
stem cells (Fig 2) [7,8,10,11].  
Cancer-associated fibroblasts  
Activated fibroblasts in the cancer stroma, often termed CAFs, are an abundant cell type of 
the TME [12]. CAFs are often identified by their spindle-shaped morphology with indented 
nuclei compared to resting fibroblasts, in combination with expression of typical markers 
(such as αSMA, PDGFRα/β, FSP1 and/or FAP, and the absence of epithelial, endothelial 
and immune cell markers) [10,12,13] .  
CAFs make up a heterogeneous population of mesenchymal cells with different origin, 
expression of markers and function [13-15]. While most studies have shown that CAFs can 
stimulate tumor growth and progression through particularly paracrine signaling and ECM 
production and remodeling, some CAF subsets have actually been shown to restrain tumor 
growth [10,15]. The CAF heterogeneity is manifested by the wide range of markers used 
to identify the cell type, but there is no consensus on the molecular definition of CAF 
subtypes [12,16]. Notably, no CAF-specific marker exists, and no marker is expressed by 
all CAFs, and there is a need to identify markers that can help differentiate between various 
CAF subtypes to better characterize CAF heterogeneity [12,16]. Therefore, finding ways 
to distinguish between tumor-supportive and tumor-suppressive CAFs, is probably 
necessary to identify effective CAF-targeted therapies in cancer treatment [12].   
Origin 
There is evidence that CAFs originate from different precursor cells [12,13,15]. While 
activation of tissue resident fibroblasts and recruitment of mesenchymal stem cells are well 
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documented CAF origins, other probable sources are trans-differentiation from local cells 
such as pericytes, adipocytes, smooth muscle cells, endothelial cells or tumor cells, and also 
from recruited fibrocytes [12,13,17-19]. It should be noted that some of these CAF origins 
are still controversial, for example derivation from tumor cells by epithelial-to- 
mesenchymal transition (EMT) [13]. Most studies find CAFs to be genetically stable, and 
the lack of mutations in this cell population questions the existence of a tumor cell-derived 
CAF subpopulation or indicate that this subpopulation is at least a small minority [20]. 
However, in a recent work of Bartoschek and colleagues, a subpopulation of CAFs isolated 
from breast cancer in PyMT mice was found to share gene expression and the PyMT 
oncogene with the tumor cells, indicating that this small cell population might have 
epithelial origin [21]. So indeed, the origin of CAFs remains an issue of debate and should 
be further explored to enlighten the heterogeneity of CAFs. 
Activation of fibroblasts 
In normal tissue, fibroblasts are usually considered to be quiescent mesenchymal cells 
embedded within the interstitial ECM, but during tumor initiation and progression the 
majority of the fibroblasts acquire an activated phenotype [12,16,17]. Activated fibroblasts 
are typically more contractile, migrative and proliferative, with increased secretion of 
signaling molecules and ECM components compared to their resting counterparts 
[12,16,17]. The recruitment and activation of fibroblasts are driven by the release of 
fibroblast-activating factors like TGF-β, FGFs, PDGFs, but also through other mechanisms 
such as increased stiffness [12,13,16,17].  
Dvorak suggested in 1986 that malignant tumors “invoke the wound healing response to 
induce the stroma” required for their own survival and growth [22]. This became a seminal 
paper in the field of TME biology, and now, the similarities between wound healing, 
fibrosis and tumor stroma generation are well recognized where fibroblasts with an 
activated phenotype, often called myofibroblasts, share similar functions [10,23]. 
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Fig 3. A tumor is a wound that never heals; the wound healing, fibrosis and cancer triad. 
Myofibroblasts are responsible for ECM production, remodeling and tissue contraction in wound healing, 
fibrosis and in the tumor stroma, and integrin α11β1 has been found to be important for fibroblast function 
in all these conditions. The red lines represent αSMA and the blue lines collagen. Reprinted from [24], with 
permission. 
Myofibroblasts 
The terminology used to describe fibroblasts in the cancer stroma is not consistent, and 
CAFs are most often used as a “collective term” describing all fibroblast-like cells with an 
activated state in the cancer stroma, but names like tumor-associated fibroblasts and 
myofibroblasts are also used [10,12]. As different fibroblasts vary in their secretory, 
proliferative and contractile abilities, the term myofibroblasts is now often used to describe 
CAFs that resemble myofibroblasts seen in the process of wound healing and fibrosis; i.e. 
fibroblasts with enhanced contractility due to upregulation of the contractile form of actin, 
αSMA [10,16,25]. Further, myofibroblasts are regarded as the cells responsible for 
excessive ECM production [16,25,26]. In a healing wound, myofibroblasts will contract the 
wound and secrete ECM proteins, thereby generating a mature connective tissue stroma, 
and finally when the wound is healed, they will revert to quiescent fibroblasts or undergo 
apoptosis [25,27]. On the contrary, the wound healing process is sustained both in fibrosis 
and in cancer with persistent inflammation, fibroblast activation and thereby continuous 
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ECM production and modification, resulting in excessive ECM deposition [25,27]. This is 
often referred to as the desmoplastic reaction [10]. Integrin α11β1 has emerged as a new 
myofibroblast marker as it has been found to be upregulated in fibroblasts during their 
differentiation into myofibroblasts [28-30]. 
Tumor-supportive functions of CAFs 
Extensive experimental data have shown that activated fibroblasts can increase cancer 
aggressiveness [12,20]. CAFs contribute in different ways to the promotion of tumor 
growth and invasiveness; they stimulate tumor cell proliferation and survival, promote 
invasion and metastasis, stimulate maintenance of cancer stemness, and can also increase 
therapy resistance [12,15,20].  
Once activated, CAFs commonly secrete pro-tumorigenic growth factors and cytokines 
such as HGF and PDGFs. In addition, CAFs also influence tumor cells indirectly through 
modulation of the TME; by ECM production and modification, by promoting angiogenesis, 
and the last decade, their interaction with immune cells have been highlighted. Indeed, 
CAFs can increase the pro-tumorigenic inflammation seen in many carcinomas, and at the 
same time act immune-suppressive, reducing the anti-tumor immune response, and possibly 
also reduce the sensitivity to immunotherapy [12,13,15,17,20].  
Tumor-suppressive functions of CAFs 
Although most data demonstrate a tumor-supportive function of CAFs, some studies have 
strongly indicated that subsets of CAFs may suppress tumor growth. Two studies published 
in 2014 indicated a surprising pro-tumorigenic effect of depleting CAFs in PDAC 
(pancreatic ductal adenocarcinoma) mouse models. First, Ozdemir et al. conditionally 
depleted proliferating αSMA-expressing cells in a PDAC mouse model, which resulted in 
more aggressive tumors [31]. Noteworthy, in this study, all αSMA-positive cells were 
depleted, not only αSMA-positive CAFs. Similarly, Rhim et al. demonstrated with a 
 18 
different PDAC model, a pro-tumorigenic effect of suppression of Hedgehog signaling in 
pancreatic epithelial cells and thereby reduction of stromal αSMA-positive cells [32].  
Later, other reports have highlighted the heterogeneity of CAFs in the cancer stroma in 
which different CAF subsets influence the tumor cells differently [19,21,33-35]. Two 
publications have interestingly highlighted CAF heterogeneity in pancreas and breast 
cancer. Ohlund and colleagues identified two subsets in PDAC; inflammatory and 
myofibroblastic CAFs (iCAFs and myCAFs), while Costa and colleagues defined four CAF 
subtypes in breast cancer. Intriguingly, the subsets seem not to represent fixed cell types, 
but rather different states of fibroblasts [10,33]. 
1.1.2 The interstitium 
The interstitium fills the space between the cells and the blood and lymph vessels, and 
consists of the structural molecules comprising the ECM, in addition to the interstitial fluid 
with its dissolved substances [36].  
Extracellular matrix 
The structural molecules of the interstitium comprise the ECM [36]. It is a complex network 
composed of a variety of macromolecules such as collagens, proteoglycans, elastin, 
fibronectin and laminins, where collagens are the most significant component [37,38]. The 
ECM acts as an architectural scaffold, provides anchorage for cells, and is a reservoir for 
various insoluble substances such as growth factors and cytokines [36,37,39,40]. 
Components of the ECM bind to adhesions receptors such as integrins, which mediate cell-
matrix adhesion and signal transduction into the cell, as well as to soluble growth factors, 
thereby regulating their distribution and activation [36-39]. The ECM composition and 
structure have a vital role in the regulation of cell behavior, and is dynamic with constant 




Collagen is the most abundant protein in the body [37]. In mammals 28 collagen types have 
been identified, and different tissues have a unique collagen composition [38,39]. 
Normally, there is a constant production and degradation, and matrix metalloproteinases 
(MMPs), inhibitors of MMPs and enzymes responsible for modifications such as lysyl 
oxidases (LOX) are important contributors in this remodeling [39].  
 
Fig 4. Collagen structure. A. Collagen structure in a tendon. Collagen molecules form triple helices which 
again assemble to form collagen fibrils. Bundles of fibrils are organized as collagen fibers. Reprinted from 
[42], with permission. B. Transmission electron microscopy image from a MDA-MB-468 tumor in an 
integrin α11 knockout mouse show collagen fibrils. 
ECM alterations in cancer 
ECM homeostasis, including collagen production, degradation and re-organization, is often 
perturbed during tumor progression, and this is mainly orchestrated by CAFs [39,41]. Many 
solid tumors are characterized by excessive collagen deposition, and the collagen is 
increasingly linearized and crosslinked during tumor progression [39,43]. Moreover, CAFs 
have been shown to collectively lead invading tumor cells by remodeling the ECM and 
producing tracks for the invading cells, and this matrix remodeling was dependent of 
integrin α3β1 and α5β1 in CAFs [44]. 
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In the case of breast cancer, Provenzano et al showed in 2008 that increased stromal 
collagen density promoted breast cancer initiation, progression and metastasis 
experimentally [45]. A few years later, they demonstrated that straightened and aligned 
collagen fibers oriented perpendicular to the tumor boundary were an independent 
prognostic factor in human breast cancer [46]. Additionally, increased collagen deposition, 
linearized, thick collagen fibers, and increased tissue stiffness have been found to be most 
prominent in the aggressive HER2 and TNBC subtypes [47]. Later, elongated, parallel 
orientated collagen fibers have been demonstrated to correlate with poor survival also in 
other cancer types [48]. Intriguingly, experimental studies suggest that collagen 
crosslinking and stiffening of the ECM play a causal role in the promotion of malignant 
transformation by enhanced integrin signaling [49]. 
Interstitial fluid pressure and transcapillary fluid exchange 
The interstitial fluid is the route of transport of nutrients, signaling molecules and waste 
products to and from the tissue cells, and the transcapillary fluid flux is therefore vital for 
normal tissue homeostasis [36,50-52]. Normally, it is formed by transcapillary filtration 
from blood capillaries into the interstitium and is finally removed by the venous side of the 
vascular system or lymphatic vessels [36,50-52].  
The transcapillary transport of molecules is primarily by diffusion and/or convection [53]. 
While diffusion is determined by a concentration gradient, convection is transport of 
molecules by fluid flow, and transcapillary convection is thereby determined by the fluid 
filtration rate across the capillary membrane [50,53]. While low molecular compounds are 
transported by both diffusion and convection, high molecular compounds are mainly 
transported by convection [50]. 
The pressures that determine the transcapillary fluid filtration rate, i.e. determine the net 
filtration pressure and thereby transport of molecules by convection, are described by the 
Starling hypothesis as [51]:  
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JV = CFC [(PC – PIF) – σ (COPC – COPIF)] 
JV = Filtration  
CFC = Capillary filtration coefficient (dependent on the area and permeability of the vessel wall) 
PC = Capillary hydrostatic pressure 
PIF = Interstitial fluid pressure,  
σ = The colloid osmotic reflection coefficient, 
COPC = Capillary colloid osmotic pressure 
COPIF = Interstitial colloid osmotic pressure 
In normal tissues, transcapillary fluid filtration is driven by the capillary hydrostatic 
pressure with additional contribution from the interstitial colloid osmotic pressure and a 
slightly negative interstitial fluid pressure (PIF) - which all drives fluid flow into the 
interstitium [50,52]. On the other hand, the capillary colloid osmotic pressure tends to keep 
fluid within the vessel. The sum of the starling forces is normally a net outward filtration 
pressure leading to fluid flow from the capillaries into the interstitium, as demonstrated in 
Fig 6 [50]. Excessive fluid is finally reabsorbed in the venous section of the capillaries or 
removed from the interstitium by lymphatic vessels to avoid fluid accumulation [50,54]. 
 
Fig 6. Transcapillary fluid flow. A. In normal tissue, there is a net outwards filtration pressure and fluid 
flows from the capillaries and into the interstitium. B. In solid tumors, PIF can be markedly elevated and 
hinders fluid flow into and within the tumor. PC = Capillary hydrostatic pressure. COPC = Capillary colloid 
osmotic pressure. PIF = Interstitial fluid pressure. COPIF = Interstitial colloid osmotic pressure. 
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On the contrary, the vasculature is markedly changed in tumors; the blood vessels are 
hyperpermeable, and lymphatic vessels are dysfunctional or missing [50,53]. The leaky 
blood vessels increase the flux of fluid and plasma proteins into the tumor interstitium and 
at the same time there is reduced lymphatic reabsorption which will lead to fluid 
accumulation in the tumor interstitium and thereby increased tumor PIF [53,54]. Additional 
factors that may contribute to increased tumor PIF are a dense ECM which reduce the 
leakage and escape of fluid, in addition to contractile fibroblasts which are thought to exert 
a tension on the ECM [50,53].  
Drug transport  
Cancer therapy must reach the target cells in order to exert their effects, and blood-borne 
drugs must therefore be transported across the capillary wall and through the tumor 
interstitium. Since increased tumor PIF decreases fluid transport into and within solid 
tumors, it may act as a barrier to the delivery of drugs, thereby reducing their efficiency 
[50,54]. Cancer therapy is mainly transported by convection, especially high-molecular 
compounds [50], and several studies have shown improved uptake of drugs into the tumor 
by reducing tumor PIF in some [55-58], but not all models [59,60].  
The effects of integrin α11-deficiency on tumor PIF (paper I and II), and also on the uptake 
of 3H-5FU into xenograft breast tumors (paper II), are investigated in this thesis. 
1.1.3 Integrins 
Integrins are cellular adhesion receptors that act as links between the cells and the ECM, 
and also cell-cell adhesion receptors [61,62]. They regulate diverse cellular functions 
including cell motility, proliferation and survival, and sense and react to changes in the 
microenvironment [62-64]. They are crucial for cell migration by coupling the ECM to the 




Fig 7. Integrins. A. Integrins are transmembrane heterodimers composed of one α- and one β subunit. The 
α subunit determines ligand specificity, while the β subunit is mainly responsible for intracellular signaling 
and is connected to the cytoskeleton. Reprinted from [66], with permission. B. The integrin family consists 
of 18 α and 8 β subunits which can combine to form 24 integrins. Reprinted from [61], with permission. 
Integrins are bi-directional signaling molecules with inside-out and outside-in signaling 
[61]. As they lack intrinsic enzyme activity, integrin signaling is transmitted through 
intracellular association of soluble kinases and adapter proteins upon activation of the 
receptor [62,67]. 
Integrins are expressed on all nucleated cells [68], and the integrin expression pattern and 
activation state on each cell will determine how a cell responds to its microenvironment 
and is therefore crucial for cellular responses to microenvironmental changes [62]. 
However, both the expression pattern of different integrins and their activation state are 
often transient, making integrin biology and function complex - not only dependent on cell 
type, but also on tissue type and context [61,63,69].  
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Collagen-binding integrins 
The collagen-binding integrins consist of integrin α1β1, integrin α2β1, integrin α10β1 and 
integrin α11β1, and mediate cell-collagen interactions by binding to different types of 
collagens with varying affinity [65]. Although collagen-binding integrins seem to have a 
limited role in adult connective tissue homeostasis, they are probably important in dynamic 
connective tissue remodeling such as wound healing, fibrosis and cancer [65]. 
Integrin α11β1 
Integrin α11β1 is the newest and last supplement to the integrin family, and the α11 subunit 
exclusively forms a heterodimer with the β1 subunit [24].  
Distribution 
Integrin α11β1 has been shown to be expressed on a subset of fibroblasts and mesenchymal 
stem cells [65]. In human and mouse embryos [70,71], integrin α11 protein and mRNA are 
mainly expressed in mesenchymal non-muscle cells in tissues with highly organized 
collagen, such as fibroblasts around ribs, vertebrae and in intervertebral discs. In human 
adult tissues, integrin α11 mRNA was in early studies found to be expressed in high levels 
in uterus and heart [72], but this has not been confirmed at the protein level. Although the 
expression of integrin α11β1 seems to be restricted to mesenchymal non-muscle cell at sites 
of highly organized collagen, the characterization of the expression pattern in human adult 
tissues is so far limited due to lack of specific reagent tools and low expression level in 
most tissues [24]. In a recent publication, integrin α11β1 was found to be expressed on 
osteoblasts and to be important in the regulation of osteogenesis and adult skeleton 
maintenance [73]. 
The expression of integrin α11β1 seems to be upregulated during myofibroblast 
differentiation and in CAFs [24]. In 2002, Wang et al. identified integrin α11 mRNA to be 
overexpressed in non-small cell lung cancer compared to normal lung tissue [74]. Later, 
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integrin α11 expression has been found to be upregulated in CAFs in lung cancer [75,76] 
and in oral squamous cell carcinoma [77].  
Function in vitro and in vivo 
Integrin α11β1 has been shown to bind preferentially to collagen I and is important for 
attachment and migration of cells on collagen I, and for contraction of collagen gels [70]. 
It has a role in collagen organization [70] and myofibroblast differentiation in vitro [30], 
and during wound healing [78] and fibrosis [29,79,80] in vivo. TGF-β has been shown to 
upregulate the expression of integrin α11β1 expression in multiple cell lines [81,82]. 
The integrin α11 knockout (α11-KO) mice have a relatively mild phenotype, but are smaller 
than their wild type (WT) and heterozygous littermates, especially the first weeks of living, 
and they display increased mortality [83]. A defect in incisor tooth eruption and altered 
tooth shape can partly explain this phenotype, but as the α11-KO mice are smaller already 
at birth, additional factors are likely [24]. They have for example been shown to have 
reduced serum levels of IGF1 [84]. 
Experimental studies have indicated that integrin α11β1 can contribute to fibroblast 
function in both wound healing, fibrosis and in tumorigenesis [24,65]. Regarding wound 
healing, α11-KO mice have shown reduced granulation tissue formation due to defect in 
myofibroblast differentiation, and reduced strength of the scar tissue, probably due to 
reduced collagen remodeling [78]. Further, integrin α11β1 may have a pro-fibrotic role in 
cardiac fibrosis [28,79,80,85], and α11-KO mice seem to be protected from development 
of dermal fibrosis in vivo [29]. 
A few studies have indicated that integrin α11β1 may stimulate tumor aggressiveness 
experimentally. Stromal integrin α11 was shown to stimulate lung cancer growth [75,86] 
and metastasis [86] in vivo, and lung cancer cell proliferation, invasion and migration in a 
heterospheroid model [87]. The pro-tumorigenic abilities of integrin α11β1 were in these 
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studies suggested to be related to the production of IGF2 by fibroblasts [75] and CXCL5 
by lung tumor cells [87], and also to collagen organization, tissue stiffness and the collagen 
crosslinking enzyme, LOXL1 [86,88].  
Additionally, it should also be noted that a few studies have indicated that integrin α11β1 
could have a role in the regulation of dermal PIF in vivo [89,90] and PIF in lung cancer 
heterospheroids [87]. In paper I and II, we have investigated the effect of stromal integrin 
α11 on breast tumor growth, collagen organization and tumor PIF using α11-KO mice. In 
paper III, the expression and prognostic impact of integrin α11 in human breast cancer 
were investigated. 
1.2 Breast cancer 
Breast cancer is the most common cancer type among women in Norway [91]. Even if 
improvements in early detection, breast cancer classification and more tailored treatment 
have considerably improved the prognosis of breast cancer during the last decades, breast 
cancer behavior, including metastatic patterns, prognosis, and response to therapy, differ 
among different breast cancer subgroups [92].  
1.2.1 Classification of invasive breast carcinoma 
Traditionally, breast cancer has been classified by clinico-pathological assessment and a 
few molecular markers [93]. The expression of estrogen receptor (ER), progesterone 
receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki67 give important 
prognostic information and directly guide breast cancer treatment [94]. However, breast 
cancer is a heterogeneous disease, and traditional markers have been shown not to fully 
reflect the biological heterogeneity of breast cancer [93,95]. With the aim of better 
individualized therapy, enormous amount of work has been done to further characterize this 
heterogeneity and to develop better prognostic and predictive markers [93]. 
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Histological classification 
Breast carcinomas are classified according to their morphological appearance. The majority 
of invasive breast carcinomas are classified as invasive carcinoma of no special type (NST) 
which means that >50% of the tumor does not fit into a defined special subtype [93,96]. Of 
the special types of invasive breast carcinoma, the most common type is invasive lobular 
carcinoma [93,96]. Classification of breast cancer by morphology has prognostic value; the 
special types tubular and mucinous carcinoma are for example associated with good 
prognosis, while metaplastic carcinoma is associated with poor prognosis [96]. 
Molecular classification 
Great improvements in the molecular classification of breast cancer have been achieved 
over the last two decades [97]. Microarray-based gene expression profiling studies have 
demonstrated different subtypes of breast cancer based on the expression of several genes, 
also called intrinsic breast cancer subtypes (Fig 8) [98,99]. Initially, only four subtypes 
were identified; the luminal, HER2-enriched, basal-like, and normal-like [98,99]. Later, the 
luminal group has been divided into at least luminal A and luminal B, and the normal-like 
has been proposed to mainly represent contamination of normal tissue [99,100]. These 
intrinsic subtypes have shown differences in behavior, prognosis and response to therapy 
[99-101]. Efforts are ongoing to further sub-classify these subtypes, especially the basal-
like subtype that has the least favorable prognosis.  
Triple-negative and basal-like breast cancer 
Triple-negative breast cancer (TNBC) represents 10-15% of invasive breast carcinomas and 
is defined by lack of expression of estrogen and progesterone receptors and absence of 
amplification of HER2 [102]. Patients with TNBC have fewest treatment options and also 
the least favorable prognosis where a subset of patients have early disease relapse 
[103,104]. TNBC is diagnosed by exclusion of other breast cancer types, and therefore 
represents a heterogenous disease regarding biology and clinical behavior. Noteworthy, 
 28 
TNBC and the basal-like subtype are mostly overlapping, where around 70% of basal-like 
tumors are TNBC, and 80% of TNBC are basal-like [102]. Gene expression analyses have 
further subclassified TNBC [105,106], and differentiation by immune-, mesenchymal-, 
stem cell-, basal and also androgen markers have given important biological information 
about the molecular differences in TNCB, and have provided frameworks for studies of 
more targeted therapies in TNBC [102].  
 
Fig 8. Molecular classification of breast cancer. Pioneer work has identified the existence of distinct 
molecular subtypes of breast cancer. Modified from [101], with permission. Copyright (2003) National 
Academy of Sciences, U.S.A. 
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Prognostic and predictive markers in breast cancer 
Several prognostic markers guide breast cancer treatment (and are therefore also predictive 
markers); TNM stage (tumor size-nodes-metastasis), histologic grade, mitotic count, 
hormone receptors, HER2-status, and also Ki67, and these markers are routinely reported 
in pathology reports of invasive breast carcinoma [107]. 
Based on the studies of molecular classification of breast cancer, gene expression tests such 
as Oncotype Dx, Mammaprint and Prosigna have been developed and provide prognostic 
information. These are now being introduced in the clinic, and the Norwegian Breast 
Cancer Group recommends the test Prosigna for use in some subgroups of breast cancer 
patients to help guide adjuvant treatment [107]. 
1.2.2 The tumor microenvironment of breast cancer 
Breast cancer consists not only of tumor cells, but as for other solid tumors, of an intricate 
TME that significantly influences breast cancer development, progression and therapeutic 
response [108,109]. Altered signaling pathways and molecular changes in stromal cells 
indeed characterize the breast cancer TME, and many of these alterations or signatures have 
been shown to predict patient outcome and response to therapy [108,110-112]. Extensive 
research is now done to find prognostic and predictive stromal markers, and in the 
development and testing of different stromal therapeutic targets [108]. 
Breast CAFs as prognostic markers 
Breast cancer is often regarded as desmoplastic tumors were CAFs are the main regulator 
of ECM deposition and remodeling [10]. Extensive experimental data have demonstrated 
that breast CAFs can stimulate breast cancer growth and progression [113]. Further, the 
heterogeneity of breast CAFs has recently been highlighted [19,21,34,35], and several 
studies have aimed to identify tumor-supportive CAF subtypes with prognostic value.  
 30 
αSMA-positive fibroblasts are more abundant in invasive breast carcinomas compared to 
normal breast tissue and benign lesions [114,115]. High stromal αSMA expression has been 
associated with aggressive breast cancer phenotypes and has been shown to predict poor 
prognosis in some studies [114,116-120]. However, αSMA-positive fibroblasts, often 
referred to as myofibroblastic CAFs (myCAFs), surprisingly seem to represent a CAF 
subset with tumor-suppressive functions in PDAC [121], and future experimental research 
should investigate if these findings are transferable to breast cancer. High PDGFRβ 
expression has also been associated with aggressive breast cancer phenotypes and can 
predict poor prognosis and therapy response [122,123]. Furthermore, several studies of 
FAP expression in various cancers have given conflicting results, where FAP’s prognostic 
value varies from study to study which has been suggested to reflect the lack of specificity 
of several commercial antibodies [124].  
Costa and colleagues identified one breast CAF subset (CAF-S1) expressing high levels of 
αSMA and FAP which was localized in close proximity to the tumor cells. This subtype 
was found to attract T-cells and to contribute to immunosuppression. However, none of the 
four CAF subsets identified in this study could predict patient survival although both CAF-
S1 and CAF-S4 were associated with the TNBC subtype [34]. In another study, Su et al. 
characterized a CAF subtype positive for both CD10 and GPR77 that promoted tumor 
formation and chemoresistance, and also reflected patient outcome and treatment response 
in several breast cancer cohorts [35]. 
Nevertheless, even if several studies have implicated that at least some CAF subsets can 
have prognostic and predictive value in breast cancer, for several markers the results are 
partly conflicting, and more research is highly warranted.  
Tumor microenvironment in TNBC 
Also, regarding the TME, TNBC seems to be markedly heterogenous, and indeed, features 
of the TME have shown to predict outcome [125]. Number of tumor-infiltrating 
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lymphocytes seen by immunohistochemistry (IHC) are a well-known predictor of good 
prognosis of TNBC, but lately, more complex and deeper characterization of the TME in 
TNBC seems to provide additional prognostic information [125]. For example, a recent 
study demonstrated that not only the frequency, but also the location of tumor-infiltrating 
lymphocytes correlated with gene signatures and clinical outcome [126]. In the future, more 
detailed characterization of the TME will hopefully contribute to the identification of 
distinct TNBC phenotypes, with the aim of more personalized therapy in this aggressive 
breast cancer subtype. 
Breast myoepithelium 
The epithelium of the mammary gland consists of an inner luminal and a surrounding 
myoepithelial cell layer [127]. The myoepithelial cells are important for normal mammary 
gland development by influencing the polarization of the luminal epithelium and branching 
of the mammary ducts, and also milk production [128,129]. The myoepithelial cells are 
contractile, which is important for their function in milk ejection during lactation [128].  
The presence of malignant cells outside the myoepithelium and basement membrane 
discriminates in situ lesions from invasive carcinoma [130]. As visualization of the 
basement membrane is challenging in tissue sections, identification of a myoepithelial cell 
layer is therefore a surrogate marker of an intact basement membrane and is of huge 
importance in the diagnosis of invasive breast carcinomas [130]. The myoepithelial layer 
can most often be easily identified with markers such as αSMA and cytokeratin 14 (CK14), 
but there can sometimes be challenges in the histological interpretation; the myoepithelial 
layer may be interrupted and/or express an altered immunoprofile, and in some non-
malignant lesions, such as in microglandular adenosis, the myoepithelial layer is absent 
[130].  
Myoepithelial cells are thought to play a part in the early stages of breast cancer 
tumorigenesis [131]. Normally, they act as a physical barrier that together with the 
 32 
basement membrane separate the stroma from the epithelial cells, and can also be active 
tumor suppressors [130,131]. Sirka et al. demonstrated that myoepithelial cells can actually 
restrain and recapture invasive breast cancer cells [131]. Recent data have shown that 
DCIS-associated myoepithelial cells are altered compared to myoepithelial cells in normal 
breast tissue [130,132]. Further, the tumor-suppressive functions of myoepithelium may be 
lost with DCIS progression, and loss of this suppression has been suggested as at least a 
contribution to the transition from preinvasive to invasive cancer [129]. In pre-invasive 
breast lesion, these differences have been suggested as possible markers for risk-
stratification or targets for prevention of invasive breast cancer.  
Integrin expression in breast myoepithelial cells 
Myoepithelial cells express integrins that are important for attachment of the cells to the 
basement membrane, which is mainly formed of collagen IV and laminins [133]. The 
collagen-binding integrins α1β1 and α2β1 have collagen IV as a known ligand and are 
expressed in myoepithelial cells [65]. Integrin α11β1 binds to collagen IV with low affinity 
and has not been shown to bind to other components of the basement membrane [65,70]. 
The expression of integrin α11β1 expression in breast myoepithelial cells is discussed in 
paper III.  
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2. Aims of the study 
Overall aim:  
To investigate the role of integrin α11β1 in breast cancer. 
Specific aims: 
1: Examine the role of stromal integrin α11β1 in experimental breast tumor growth, 
collagen organization and interstitial fluid pressure regulation using different integrin α11-
deficient mouse models (paper I and II). 
2: Establish conditions for reproducible staining of integrin α11 in formalin-fixed, paraffin-
embedded human tumor material using new antibodies against the integrin α11 subunit 
(paper III). 
3: Investigate the expression pattern of integrin α11 in human breast cancer, and based on 
this, examine the association of stromal integrin α11 expression with aggressive breast 
cancer phenotypes and potential prognostic impact in human breast cancer (paper III). 
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3. Methodological considerations 
The methods used in paper I-III are described in detail in the respective manuscripts, but 
some essential methodological aspects are discussed in the following sections. 
3.1 Mouse models for studying the tumor microenvironment 
Mice play an essential role in breast cancer research, and mouse models represent an 
important step between in vitro experiments and clinical studies [134]. They are easy to 
handle, breed effectively, have molecular and physiological resemblances to humans, and 
provide us with research opportunities like standardized study populations and the 
possibility of genetic modifications [135,136]. The last decades, there has been enormous 
growth in the number and sophistication of mouse models for cancer research [136].  Since 
all mouse systems have their strengths and limitations, and different models give 
complementary information, various mouse models should be investigated to maximize 
what can be learned from them [136]. However, animal welfare should be central when 
working with mice, with special focus on replacing animal experiments if possible, 
reducing the number of animals, and refining the experiments i.e. make sure the animals 
suffer as little as possible (the 3Rs).  
Mice have been essential for the work presented in paper I and II and have also enabled 
the generation of new anti-human integrin α11 antibodies used in paper III. 
Engraftment of cancer cell lines 
In paper I and II, murine (I) and human (II) cancer cell lines were injected into severe 
immunodeficient (SCID) WT and SCID α11-KO mice. SCID mice have a severe deficiency 
in mature B and T lymphocytes [137]. The engraftment of cancer cell lines in mice has 
provided enormous knowledge about breast cancer biology, and is the most commonly used 
mouse cancer model, as it is simple and relatively rapid to establish, and also homogenous 
 35 
and therefore requires reduced number of animals compared to other models [134]. Further, 
there are numerous, diverse and well-characterized cell lines that represent different cancer 
types and also different cancer subtypes. Nevertheless, engraftment of cancer cell lines does 
not reflect the intratumor heterogeneity of human carcinomas, represents late stages of 
primary tumor evolution since the cancer cells are derived from highly aggressive tumors, 
and probably most important for the investigation of integrin α11β1, the stromal infiltration 
is often scarce and highly homogenous compared to human cancers [134,136,138]. Indeed, 
as many of the cancer cell lines are highly aggressive, they may not be that dependent of 
stromal interactions to grow, invade and spread. Additionally, when using immunodeficient 
mice, this model does not incorporate the impact of the immune system on the tumor 
response [136], which is a concern also when investigating CAFs. Indeed, different 
components of the tumor interact with each other, and CAFs have been shown to influence 
tumor cells through immunomodulation [17,77]. Therefore, even if the engraftment of cell 
lines to WT and α11-KO mice (paper I and II) does provide important information about 
integrin α11’s role in breast cancer, these projects should be complemented with other in 
vivo and in vitro systems.  
When engrafting mouse cancer cell lines to mice, syngeneic models offers the “advantage 
of studying cancer biology within the context of an intact immune system and species-
specific TME” [136]. However, mouse cancer cells were injected into immunodeficient 
mice in paper I, and although we would have preferred to use syngeneic mouse cells in 
immunocompetent mice, the SCID α11-KO mice were the only strain available for our 
purpose. Further, we used the extremely rapidly growing tumors 4T1 and RM11 in paper 
I, and in paper II we choose cell lines growing more slowly and thus possibly more 
stromal-dependent. 
Ideally, different cell lines and different models should be investigated to reflect the 
complexity of breast cancer including all breast cancer subtypes. In paper II, we initially 
tried to use other cell lines (MCF7 and BT474). However, mice in these pilots showed 
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severe side effects of supplemented hormone treatment despite low dosage 17β-estradiol 
(0.18 mg/pellet and custom-made 0.1 mg/pellet), and the pilots were thus terminated due 
to animal welfare. Therefore, only TNBC cell lines were used in paper I and II. 
The cell lines in paper I and II were injected orthotopically and/or ectopically. Orthotopic 
implantation is regarded to be superior to ectopic implantation in engraftment models [138], 
as discussed in paper I. Nevertheless, it should be noted that the architecture of the murine 
mammary tissue is substantially different compared to the mammary tissue in humans 
especially in regards to stromal components as seen in Fig 9 [113,127,139].  
 
Fig 9. Human and murine mammary tissue. There are notable differences between human and 
murine mammary tissue architecture including differences in the stromal components surrounding 
the mammary epithelium. In humans, the ducts and lobules are embedded in loose connective tissue 
(A), while the murine stroma is mainly composed of adipose tissue and markedly less fibroblasts 
and ECM (therefore often referred to as mammary fat pad) (B). Reprinted from [113], with 
permission.  
Knockout mice 
In conventional genetically modified KO-mice, such as the α11-KO mice, a functional gene 
has permanently been deleted or inactivated within the whole mouse [140]. This model 
provides a valuable tool for studying the function of a specific gene, but several 
complicating factors can influence the results from such studies. When comparing 
differences between tumors in WT and KO-mice, the study groups should ideally be 
identical beyond the function of the gene in the investigated tissue. In regard to integrin 
 37 
α11β1, the α11-KO mice have a fairly mild phenotype, but are significantly smaller than 
their WT littermates at young age. They have reduced capability to eat food of solid material 
because of tooth defects, and both WT and α11-KO mice were therefore given powder food.  
Additionally, compensatory mechanisms may take over a gene’s function when it is 
inactivated, and there have been conflicting results regarding compensatory mechanisms as 
a result of integrin α11 deletion [71,75,89]. Consequently, the above-mentioned factors 
contribute to study groups that are not completely identical representing a bias in paper I 
and II. Production of a conditional α11-KO mouse model, in which the gene knockout can 
be spatially and temporally regulated [140] would be highly valuable. 
Other mouse models relevant in the study of TME 
In genetically engineered mouse models where oncogenes or tumor suppressor genes have 
been manipulated, the tumor develops through different stages of epithelial transformation 
and evolves within the context of a TME that more accurately reflect human disease, 
including a well-functioning immune system, stromal remodeling, angiogenesis and 
inflammation [136]. Therefore, these models are especially relevant for the study of the 
stepwise breast cancer progression and also to investigate features of the TME. The 
MMTV-PyMT breast cancer mouse model has been recognized for its relevance in the 
study of breast CAFs since the carcinomas in this model consist of a fibroblasts-rich, 
fibrotic stroma resembling human carcinomas, and the expression of different CAF markers 
is remarkable similar as in human carcinomas [141]. Interestingly, a collaborating group 
has crossed the MMTV-PyMT mice with α11-KO mice to investigate the role of integrin 
α11 in breast cancer [142]. This model resembles human breast cancer of the luminal B 
subgroup (ER and HER2-positive) [141], and thus, additional models are needed to 




CAF heterogeneity in experimental breast cancer models 
A very recent study of breast CAF heterogeneity demonstrates that CAFs show obvious 
heterogeneity across different murine TNBC tumors, indicating that cancer cell intrinsic 
factors may strongly affect the CAF subpopulations [143]. Further, the expression of 
different CAF markers changes during tumor progression even in the same tumor model 
[143], and integrin α11 expression in PyMT tumors indeed seem to display temporal 
heterogeneity [142].  Therefore, CAF heterogeneity in relation to different tumor models, 
and also to temporal intratumoral heterogeneity, may explain conflicting results when 
investigating CAFs experimentally. Of note, most measurements in paper I and II were 
done at end point day and investigations during different time spans in these models could 
give additional information.  
3.2 Collagen analyses 
In paper I and II, different methods were used to study collagen. Picrosirius red staining 
is a simple and sensitive method to identify fibrillar collagen in tissue sections [144], and 
was used to investigate the amount of collagen in the engrafted tumors. While some reports 
indicate that it can distinguish between collagen I and III according to their colors under 
polarized light, this has been an issue for debate [145], and this approach was not used. 
However, we additionally performed IHC staining of collagen III in paper II.  
Electron microscopy offers high magnification images and was therefore used to investigate 
collagen fibril structure and organization. However, due to the limited field of view, it 
provides minimal information about collagen fiber organization.  
3.3 Measurement of intersititial fluid pressure 
In paper I and II, the wick-in-needle and micropuncture technique were used to measure 
PIF in engrafted tumors and in heterosperoids, respectively. Both methods are well-
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established in our group. The micropuncture technique gives highly reproducible PIF, 
induces little tissue trauma and should be chosen whenever applicable [52]. However, it 
can only record PIF down to 1 mm below the surface and is therefore not suitable for 
measurements of PIF in tumors, but is usually chosen to measure PIF in heterospheroids 
due to their small size [52], as we did in paper II. 
The wick-in-needle technique has the great advantage that it can record deep in tissues and 
is regarded as standard method for measuring PIF in engrafted tumors [50,52]. Although 
tissue trauma usually always will occur to some degree, comparison between 
micropuncture and wick-in-needle technique has shown similar pressures [50,52]. In paper 
I and II, tumors with evident bleeding during the PIF measurement, seen as a continuous 
fall in PIF or blood stain on the wick upon removal from the tumor, were excluded.  
3.4 Breast cancer series 
The breast cancer cohort used in Paper III is a retrospective, population-based patient 
series, including women aged 50-69 years when diagnosed with primary breast cancer in 
Hordaland County during 1996-2003. Patients with distant metastatic disease at time of 
diagnosis were excluded. Follow-up data (survival status, survival time and cause of death) 
were collected from the Norwegian Cause of Death Registry of Norway, the Cancer 
Register of Norway and also patient records. No patients were lost to follow-up. Treatment 
and response to treatment were not registered, but the patients received treatment according 
to standard treatment protocols at that time.  
Population-based series reduce the risk of sampling bias which can increase the 
applicability of the generated results to the general breast cancer patient population. An 
additional advantage of this patient series is long and complete follow-up data on both 
incidence and outcome. However, only women with primary breast cancer aged 50-69 years 
old were included, and results generated from this cohort may not be generalizable to 
patients younger than 50 years and older than 69 years. Additionally, anti-HER2 treatment 
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was not standard as adjuvant treatment of primary breast cancer in the period of 1996-2003, 
and therefore, patients diagnosed with HER2-positive breast cancer receiving standard 
treatment today have a markedly improved prognosis compared to HER2-positive breast 
cancer patients enrolled in this study. 
3.5 Immunohistochemistry 
IHC visualizes antigens within tissue sections by binding of a labelled antibody to its 
antigen [146]. It enables determination of the spatial distribution of one or more proteins in 
tissues and semi-quantitative quantification of the target protein [146,147]. IHC was used 
in all papers in this thesis.  
Although IHC analyses are easy, inexpensive and widely used both in routine pathology 
and in research, the technique has several pitfalls that can cause both false positive and false 
negative staining results and thereby lead to incorrect conclusions [146,148,149]. Indeed, 
variations in both the pre-analytic, analytic and post-analytic phase can contribute to bias 
in the IHC results [146,147].  
The impact of different variables on the IHC results is antigen-, antibody- and also tissue-
and preparation-dependent [146,147]. Therefore, before introducing a new IHC protocol, 
the protocol should be properly validated and optimized using tissues with the same pre-
analytic, analytic and post-analytic treatment as the tissue to be tested. Validation of an IHC 
protocol is important when using new antibodies or “old” antibodies in a new setting, and 
to enable inter-laboratory comparison and standardization. In paper I and II, already well-
established IHC protocols were used. In paper III, efforts were made to properly validate 
new monoclonal antibodies and establish the IHC protocol. 
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Pre-analytical varibles 
Pre-analytical variables can significantly impact the IHC staining result [146,147]. As the 
sections for the cohort in paper III were assembled prior to the current study, variables 
such as time to fixation, fixation time and paraffin impregnation were not available to 
adjustment. Therefore, we cannot exclude influences on antigenicity of the integrin α11 
epitope by these variables.  
Antibody validation and IHC controls 
Lack of proper antibody validation and appropriate IHC controls contribute to the 
difficulties seen in reproducing IHC-derived data; and even more seriously, improper 
validated IHC protocols can generate reproducible, but incorrect conclusions [148]. To 
ensure correct and consistent results, optimized and standardized tissue protocols are 
required [147,148]. This includes proper validation of the primary antibody and careful 
selection of positive and negative controls [148]. 
Appropriate controls are crucial to ensure that the obtained IHC result is a consequence of 
binding of the primary antibody to the correct antigen in tissue sections [148]. The controls 
should confirm that the primary antibody only binds to the correct antigen, that the labelling 
observed is due solely to binding of the secondary antibody to the primary antibody and 
that the labelling is not a result of endogenous fluorescence or enzyme reactivity (for 
example endogenous peroxidase) [148]. An overview over recommended controls in IHC 
is summarized in Table 1.  
In regard to fibroblasts markers, investigations of FAP in human material have shown 
different, often contradicting results [124]. As reported by Pure and Blomberg, several 
commercially available anti-FAP antibodies lack specificity, and studies using immune-
based assays with antibodies against FAP should be interpreted based on inclusion of 
appropriate controls [124]. Similarly, to our experience, most commercially available 
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antibodies against integrin α11 do not show specific binding in FFPE tissue. As an example, 
a previous study investigating the expression and prognostic impact of integrin α11 in a 
series of 80 FFPE invasive human breast carcinomas obtained contrasting results to our 
study. They reported that integrin α11 was strongly expressed in the tumor cells and no 
staining of the stromal compartment was described [150]. The anti-integrin α11 antibody 
Reagent controls Biological controls 
Positive reagent control 
A different antibody against the same protein. 
 
Positive tissue control 
Tissue known to express the protein. The protein 
should ideally be expressed in stable levels, with 
different intensity (low to high). 
 
Types of positive tissue controls 
a. External tissue control 
b. Internal tissue control 
c. Cell pellet control: cell line with known 
expression or transfected with the target protein 
Negative reagent control 
a. Isotype control 
Isotype-specific immunoglobulin at the same 
concentration as the primary antibody. Control for 
non-specific interaction of the antibody with the 
tissue and the detection system. 
 
b. Antibody diluent control 
Omitting the primary antibody. Only a control for 
the detection system beyond the primary 
antibody. 
Negative tissue control 
Tissue known to not express the protein. 
 
Types of negative tissue controls 
a. External tissue control 
b. Internal tissue control 
c. Cell pellet control: cell line known to not 
express the target protein/non-transfected cell or 
knock down of the expression of the target 
protein 
Table 1. IHC controls. An overview over recommended IHC controls. In addition, absorption 
control/competitive blocking is often used to verify the primary antibody specificity [147,148,151]. 
Ideally biological controls should be fixed, 
processed and analyzed in the exact same manner 
as the test sample.  
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used in this study has been shown to lack specificity in our laboratory and no IHC controls 
were reported in their study, and we believe that conclusions from studies using anti-
integrin α11 antibodies should be interpreted with caution if proper controls are not 
reported. 
Controls in paper I and II 
For the IHC experiments in paper I and II, an isotype control has been used whenever 
applicable. Internal controls have been used for αSMA and PDGFRβ and a positive tissue 
control for integrin α11-expressing mouse tissue.  
Antibody validation and controls in paper III 
In the initial screening of different clones, clones reactive to integrin α11 were included, 
and clones with cross-reactivity to other proteins of human and mouse origin, especially 
against other integrins, were excluded [81]. The clones were then investigated by western 
blotting and immunofluorescence staining of cells.  
 
Fig 10. Anti-human integrin α11 antibodies. Monoclonal mouse anti-human integrin α11 antibodies were 
produced against the extracellular (by NanoTools) and the intracellular (by Oslo University Hospital) 
domain of the integrin α11 chain (A). The antibodies were tested with different methods including western 
blotting (not shown) and immunostaining of cells and tissue sections. Immunofluorescence staining of 
C2C12-α11 cells with D120.4 (B). Immunostaining of a PDAC cryosection with 203E3 (NanoTools) (C) 
and a FFPE section of invasive breast carcinoma with 210F4B6A4 (NanoTools) (D). Own unpublished data. 
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Reagent controls 
A positive reagent control is preferable when testing new antibodies. During the production 
and characterization of the new monoclonal antibodies, supernatants from numerous 
hybridomas were screened and tested in different conditions. Although several clones 
showed the same staining pattern on FFPE material, clone 210F4B6A4 used in paper III 
was clearly superior in this condition, and a positive reagent control was not available for 
FFPE material.  
Another clone, 203E3, has recently been shown to be superior in immunostaining of 
cryosections [81], and was therefore used as a positive reagent control for immunostaining 
of cryosections in paper III in addition to a previously validated polyclonal antibody 
[72,75,152].  
IgG2b in same concentration as 210F4B6A4 was used as negative reagent control (isotype 
control). 
Biological controls 
Since antibodies should be validated in the condition where it is applied, we made different 
FFPE cell pellets to show the specificity and sensitivity of the antibodies on FFPE material. 
The following cells were used:  
- C2C12-α11 (positive control); mouse myoblast cell line that lacks endogenous collagen-
binding integrins overexpressing human integrin α11β1 – to identify clones reactive to 
human integrin α11. 
- C2C12- α2 (negative control); mouse myoblast cell line that lacks endogenous collagen-
binding integrins overexpressing human integrin α2β1 – to exclude clones with cross-
reactivity to human integrin α2. 
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- U2OS (positive control); human osteosarcoma cell line expressing low levels of integrin 
α11. Ideally, biological controls should express the protein of interest in different 
intensity levels [148]. Since transfected cell lines like the C2C12-α11 tend to display 
only high expression levels, addition of a low expressing cell line was valuable when 
calibrating the IHC protocol.  
- HEK293 (negative control); human embryonic kidney cell line not expressing human 
integrin α11 – to identify clones with cross-reactivity against other human 
integrins/proteins. 
Tissue sections were also used when validating the antibodies and calibrating the IHC 
protocol. As other anti-integrin α11 antibodies only are reliable on cryosections, we used 
corresponding cryo- and FFPE sections from the same tumors where the polyclonal integrin 
α11 antibody and 203E3 were used as controls for the cryosections. Unfortunately, we did 
not have corresponding cryo- and FFPE sections from invasive breast carcinoma, and we 
therefore used PDAC sections where integrin α11 recently has been shown to be highly 
expressed [81]. After optimizing the IHC protocol on FFPE sections from cell pellets, 
PDAC and invasive breast carcinomas, similar expression and intensity levels of integrin 
α11 staining were seen in corresponding cryo- and FFPE PDAC sections. These sections 
were then used as positive biological controls. 
To conclude, when staining the breast cancer series, the following controls were included 
in each run:  
- Serial sections of one invasive breast carcinoma; one section applied with IgG2b in 
same concentration as 210F4B6A4 (negative reagent control), another with 210F4B6A4 
(positive biological control). 
- Positive and negative cell pellet controls (positive and negative biological controls). 
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The antibody validity was also strengthened by the fact that clones against extracellular 
(NanoTools clones) and intracellular epitopes (Oslo clones and polyclonal antibody) 
showed similar results in western blotting and immunostaining. Furthermore, 
correspondence between mRNA and protein expression provided additional support for 
antibody specificity and sensitivity.  
In our laboratory, several commercial antibodies were shown to lack specificity and were 
therefore not used in this thesis.  
Optimizing the IHC protocol in paper III 
The staining protocol was optimized by testing different clones and different retrieval 
systems, such as microwave oven and pressure cooker with different retrieval buffers, and 
also enzymatic retrieval. Optimal titration of the primary antibodies was obtained through 
testing of different concentrations of the antibody.  
As demonstrated in Fig 11, we were not able to visualize integrin α11 in FFPE material 
with the use of “standard” antigen retrieval protocols, resulting in false negative results, 
and high temperature was crucial to unmask the epitope. Extensive testing of different 
protocols was done to find the most gentle antigen retrieval that was able to unmask the 
epitope with high sensitivity, but also the final protocol was hard on the tumor tissue, 
resulting in a high degree of loss of sections. In the breast cancer series used in paper III, 
25% of the cases were excluded because of insufficient remaining tissue after the antigen 
retrieval protocol, and these “drop-out” cases were not equally distributed across molecular 
subtypes of breast cancer. This is of course a clear bias, and efforts were made to reduce 
the loss of tissue, such as baking of the sections, use of poly-lysine coated glasses and 




Fig 11. Integrin α11 expression in human invasive breast carcinoma (A and C) and C2C12- α11 cell 
pellets (B and D) by IHC with different antigen retrieval protocols. Note that pressure cooker 120° for 10 
min (C and D) was clearly superior to microwave 20 min (A and B). Own unpublished data. 
Muliplex IHC 
When doing multiplex IHC, the antigen retrieval protocol used for integrin α11 single 
staining was used for the sections to be used in mulitiplex IHC. In advance, serial sections 
of different invasive breast carcinomas were stained, comparing the expression pattern and 
intensity of staining obtained by using pressure cooker 120° 10 min pH9 with the standard 
antigen retrieval protocols for the specific antibodies (αSMA, CK14 and FVIII). This was 
to ensure that with a different antigen retrieval protocol, similar expression was obtained as 
with the standard antigen retrieval protocol.  
One should be aware that with chromogenic IHC that aims to demonstrate co-localization 
with the result of a mixture of colours, spectral differentiation of the colour used may be 
challenging to the visual eye. Therefore, we choose colours that should be easy to define 
separately, and also contrast well with the mixed colours. However, the colour mixture is 
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often most visible with even intensity levels of the proteins, and if one of the proteins is 
more abundant, it will tend to dominate the other colours and it can be difficult to identify 
the low expressing antigen. However, this is avoided with the use of immunofluorescence 
staining where you can investigate each antibody reaction in different channels and 
afterwards merge the colours. We used triple chromogenic IHC with integrin α11, αSMA 
and FVIII, and concluded that integrin α11 and αSMA co-localized, but not completely. In 
addition, we also performed double immunofluorescence staining with integrin α11 and 
αSMA to verify this finding (not shown in paper III). 
Evaluation of IHC results 
There is no consensus on how to best analyze IHC results in research. Intra- and 
interobserver variability, different scoring methods and systems, and different cut-off 
values contribute to the challenge in reproducing IHC results.  
Manual examination by a pathologist in light microscope is so far the most used method, 
but digital examination and quantification are now being increasingly used. 
Paper I and II 
Image J was used to measure the percentage of αSMA, PDGFRβ, collagen III and Sirius 
red-positive pixels in pictures taken from the tumor periphery (5-6 pictures/tumor) to 
investigate different expression levels tumors in WT and α11-KO mice, and the average 
expression level was then calculated for each tumor. The area with highest expression was 
also quantified (i.e. hot spot method) for all the markers and showed similar results as the 
average expression level and was not reported in the publications. Alternatively, the whole 
section could have been scanned for analyses of the whole tumor.  
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Paper III 
Published literature investigating markers of breast CAFs shows a huge variation in the 
evaluation of IHC staining, which makes it challenging to compare results from different 
studies. Staining index (SI) was used to quantify the expression of integrin α11 in paper 
III. This is a well-established scoring system in our research group where the observer 
combines the score of intensity of staining with area stained, resulting in totally seven SI 
values (SI 0, 1, 2, 3, 4, 6 and 9). The number of severity levels may have an effect on the 
results; high levels of severities tend to reduce the repeatability, while few levels may 
reduce the sensitivity of the scoring system [147], therefore it has been suggested that 4-5 
levels may be “the optimal number to maximize detection and repeatability” [147] which 
is in line with the use of SI scoring system used in our group. 
Nevertheless, one should have in mind that semi-quantitative, manual scoring systems like 
SI is subjective and are therefore susceptible to observer variation and may therefore 
contribute to reduced reproducibility [147,153]. Indeed, consistency in tissue scoring can 
be difficult to maintain, especially when investigating a large cohort of samples, batches of 
samples are scored over a prolonged period of time, and also when multiple pathologists 
score different samples/cohorts [147,153]. Clearly defined scoring systems can reduce the 
inconsistency to some degree [153]. The SI scoring system has previously shown good 
intra- and inter observer agreement for other markers [154-156], but the variability of the 
integrin α11 scoring system used in paper III should ideally be examined to investigate if 
it can be consistently repeated at different times and by other observers.  
In paper III, we have reported the percentage of fibrous stroma stained for integrin α11 
and did not take into consideration the amount of stroma in each tumor. When investigating 
published literature using IHC to quantify breast CAFs, evaluation of the amount of stained 
CAFs in relation to the stromal compartment and not in relation to the total tumor area, 
seems to be the most common method [116,118,122,123,157]. This is in line with our 
evaluation in paper III. Also, quantification of the total amount of stroma compared to 
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tumor cells in the breast cancer series used in paper III is an ongoing project in the group, 
and will give additional information about the total amount of integrin α11 protein 
expression in the breast cancer sections, not only percentage of integrin α11-positive 
fibrotic stroma.  
The use of whole tissue sections is time consuming in both the analytical and post-analytical 
phase, but might give more accurate and reproducible IHC results, especially for markers 
with excessive intratumor heterogeneity. Since the expression of integrin α11 was indeed 
markedly heterogeneous (Fig S3 paper III), whole tissue sections of breast cancer samples 
were therefore used in paper III. However, sections of invasive breast carcinomas often 
contain benign-looking and pre-malignant tissue in addition to the invasive cancer cells, 
and therefore, the evaluation of whole sections can be challenging for non-pathologist since 
it is crucial to only score the invasive parts of the sections. The scoring in paper III was 
guided by a senior breast cancer pathologist and this issue was therefore avoided.  
3.6 RNA datasets 
Publicly available gene expression datasets, METABRIC discovery and METABRIC 
validation cohorts, were investigated for the expression of ITGA11. This is mRNA 
microarray-based gene expression data from invasive breast cancer and includes both 
mRNA data from the tumor cells and the stromal compartment. While we have reported 
percentage of fibrous stroma positive for integrin α11 in our protein data, the METABRIC 
datasets report the amount of integrin α11 mRNA in the sample investigated. Therefore, 
these datasets are not directly comparable to our SI scoring. 
Based on our IHC observations that integrin α11-positivity in invasive breast carcinomas 
is predominantly expressed in fibroblast-like cells, it is probably acceptable to assume that 
integrin ITGA11 expression in the METABRIC datasets, represents integrin α11 positivity 
in fibroblast-like cells. However, small contribution from myoepithelial remnants could 
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account for a minority of the integrin α11 mRNA expression seen in the METABRIC 
datasets. 
3.7 Statistical considerations 
Both Student’s t-test and Mann-Whitney U test were applied on the in vivo data in paper I 
and II; the Student’s t-test was used if the data fulfilled the criteria of normal distribution 
and, if not, the Mann-Whitney U test was performed. 
 
In paper III, the values for integrin α11 SI were dichotomized, and there was no pre-
established cut-off value for integrin α11 expression. To avoid bias by multiple testing and 
therefore over-fitting of the cut-off level to our breast cancer series, the frequency 
histograms for SI were evaluated prior to statistical analyses. Since the histograms 
demonstrated a clear binary distribution, the cases in the breast cancer series were 
dichotomized by this distribution corresponding to a cut-off value at the lower tertile. 
Pearson’s chi-square test was used to compare two categorical variables, Kruskal-Wallis 
test was used to compare integrin α11 expression across molecular subgroups, and the 
Kaplan-Meier method was used to analyze survival data with death from breast cancer as 
end-point and significance determined by the log-rank test. 
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4. Summary of results 
4.1 Paper I 
Stromal integrin α11β1 affects RM11 prostate and 4T1 breast xenograft tumors 
differently 
In this paper, we investigated the effect of stromal integrin α11-deficiency on tumor growth, 
collagen organization and interstitial fluid pressure (PIF) regulation in 4T1 mammary and 
RM11 prostate murine tumors using SCID mice deficient of integrin α11 (α11-KO mice). 
We reported reduced RM11 prostate tumor growth in the α11-KO mice compared to wild 
type (WT), but no effect of integrin α11-deficiency on tumor growth in the 4T1 mammary 
tumors. Further, lack of integrin α11 lead to a decrease in collagen fibril diameter in the 
4T1 tumors. No differences in the amount of activated fibroblasts, collagen content, 
collagen organization or PIF were found. 
4.2  Paper II 
Stromal integrin α11-deficiency reduces interstitial fluid pressure and perturbs 
collagen structure in triple-negative breast xenograft tumors  
Here, we investigated the effect of stromal integrin α11-deficiency in triple-negative breast 
cancer using the human breast cancer cell lines MDA-MB-231 and MDA-MB-468 
(orthotopic and ectopic tumors) and SCID α11-KO mice. Integrin α11-deficiency impeded 
MDA-MB-231 orthotopic tumor growth, and decreased tumor PIF and perturbed collagen 
structure with fewer aligned and thinner collagen fibrils in both orthotopic models. Despite 
decreased PIF in the orthotopic MDA-MB-231 tumors in α11-KO mice, integrin α11-
deficiency had no effect on tumor uptake of the chemotherapeutic drug 3H-5FU. No effects 
of integrin α11-deficiency were observed in the ectopic MDA-MB-231 model. 
Correspondingly, a decrease in PIF was found in spheroids composed of MDA-MB-231 
 53 
cells and α11-KO fibroblasts compared to spheroids composed of MDA-MB-231 cells and 
WT fibroblasts.  
4.3 Paper III 
Integrin α11β1 is expressed in breast cancer stroma and associates with aggressive 
tumor phenotypes 
After testing and validating several new monoclonal antibodies against the human integrin 
α11 chain, clone 210F4B6A4 was selected as the best for immunostaining of human breast 
cancer FFPE samples. We observed that integrin α11 was expressed in stromal spindle-
shaped, fibroblast-like cells where it co-localized with αSMA. Additionally, integrin α11 
was expressed in a subgroup of breast myoepithelium in predominantly premalignant 
lesions where it co-localized with αSMA and cytokeratin 14. By investigating the 
immunohistochemical expression of integrin α11 in 392 whole sections of human breast 
cancer, integrin α11 was found to be expressed in fibroblast-like cells in the stroma in 99% 
of the cases. Further, strong stromal integrin α11 protein expression (66% of cases) was 
associated with aggressive breast cancer phenotypes such as high histologic grade, 
increased tumor cell proliferation (Ki67 and mitotic count), ER negativity, HER2 positivity, 
and triple-negative phenotype, but was not associated with breast cancer specific survival. 
Additionally, in the METABRIC discovery and validation cohorts (n=1782), integrin α11 
mRNA expression was not found to be associated with breast cancer specific survival. 
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5. General discussion 
Altered integrin expression is often detected in cancer, and in accordance with the essential 
roles of integrins in various aspects of tissue homeostasis, several integrins have been found 
to play a role in tumorigenesis [62,63]. In cancers, individual integrins can be expressed on 
a diversity of cells, commonly both on tumor and stromal cells, and can have different, 
sometimes even antagonistic functions on each cell type. This makes it difficult to predict 
the net effect of the individual integrins [63]. Inhibition of integrin function in cancer has 
been broadly studied the last decades, but unfortunately, only a few clinical trials with anti-
integrin therapies have been successful in the treatment of cancer despite promising 
preclinical studies, underlining the complexity of integrin biology [62,63,68]. Integrin 
α11β1 is the last member to be identified in the integrin family and thorough investigation 
of the expression pattern and function in different cell types and in different tissues are 
necessary to understand the role of integrin α11β1 in pathological conditions such as cancer 
and fibrosis.  
Integrin α11β1 has been linked to collagen organization and tissue contraction and is 
upregulated during activation of fibroblasts. In the breast TME, fibroblasts represent a 
diverse cell type which can display both pro- and anti-tumorigenic effects, making a strong 
rationale for better characterization of CAF heterogeneity. In this setting, integrin α11β1 
could represent a functionally important receptor on breast CAFs. We have therefore 
investigated the role of stromal integrin α11β1 in experimental TNBC (paper I and II), 
and also the expression and potential prognostic impact of integrin α11β1 in human breast 
cancer (paper III) in this thesis. 
Integrin α11β1 is expressed in fibroblasts-like cells in the breast TME 
We report that integrin α11β1 is mainly expressed in stromal, spindle-shaped cells in 
implanted TNBC xenografts (paper II) and in human invasive breast carcinoma (paper 
 55 
III). Further, integrin α11β1 co-localizes with αSMA, and therefore our data strongly 
indicate that integrin α11β1 is expressed on breast CAFs both in mouse models and in 
human breast cancer. This is consistent with other recent studies supporting that integrin 
α11β1 is mainly restricted to CAFs in breast cancer [142] and also in other tumor types 
such as pancreas [81], lung [75] and HNSCC [152].  However, by the methods used in 
paper II and III, it is not possible to exclude that at least some of the spindle-shaped cells 
expressing integrin α11β1 could additionally represent other cell types, such as 
mesenchymal stem cells, pericytes or cancer cells that have undergone EMT. Therefore, 
we used the terminology fibroblast-like cells in paper III. In future research, it will be of 
importance to further characterize the fibroblast-like cells positive for integrin α11β1 in the 
breast TME, and to investigate if these cells are solely CAFs or if integrin α11β1 
additionally is expressed on other cell types, although biomarkers that clearly distinguishes 
these cells types are presently not available [10]. 
Integrin α11 is expressed on a pro-tumorigenic CAF subset 
In paper II, stromal integrin α11-deficiency led to reduced MDA-MB-231 tumor growth, 
and there was a trend towards reduced MDA-MB-468 tumor growth, while no effect on 
TNBC growth was observed in the 4T1 model in paper I. In agreement with the result in 
Paper II, a collaborative group recently demonstrated that stromal integrin α11-deficiency 
in MMTV-PyMT mice reduced breast cancer growth and metastasis. They also observed 
that the pro-tumorigenic abilities of integrin α11β1 relied on crosstalk with PDGFRβ and 
production of tenascin-C [142]. As previously mentioned, integrin α11β1 was found to be 
expressed on a subset of breast CAFs (paper II and III, [142]), and data from pre-clinical 
models therefore indicate that this CAF subset has pro-tumorigenic abilities in breast 
cancer, although this has not been consistent in all models so far.  
We further demonstrated that integrin α11β1 is associated with aggressive breast cancer 
features by investigating the immunohistochemical expression of stromal integrin α11 in a 
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large human breast cancer cohort (paper III), which is in line with the aforementioned pre-
clinical data. However, high integrin α11 expression was not correlated to breast cancer 
specific survival either at the protein or mRNA level (paper III). Of interest, Primac et al. 
have demonstrated that high ITGA11 mRNA correlated with poor prognosis in the Kaplan-
Meier plotter in human breast cancer [142]. However, they used automatic best cut off value 
in this article, which is a less robust statistical approach, and with no validation cohorts for 
this cut-off value. They further demonstrated by IHC that double α11/PDGFRβ positivity 
was associated with aggressive breast cancer features, and also to metastasis and mortality. 
Taken together, integrin α11β1 seems to be expressed on a pro-tumorigenic CAF subset, 
but does not seem to have potential as a prognostic marker alone (no significant effect in 
our study and possible weak effect in [142]). However, this should be confirmed also in 
other breast cancer cohorts.  
Integrin α11β1 as a new CAF marker 
Few markers have been validated to give predictive or prognostic information of value for 
clinical handling of cancer patients. Although some studies have identified single CAF 
markers that can predict patient outcome in breast cancer, recent studies indicate that 
combinations of different markers should probably be used to identify functionally distinct 
CAF subsets [21,34,35]. Only a few studies up till now have investigated the co-expression 
pattern of integrin α11 with other CAF markers. Both in human breast cancer (paper III), 
and also in implanted murine TNBC (paper II), integrin α11 co-localized with αSMA, but 
some subsets were only positive for one of the markers. The number of cases investigated 
was, however, limited. In another breast cancer cohort, integrin α11 strongly associated 
with PDGFRβ and Tenascin C, which are both expressed on CAFs in human breast cancer 
[142]. In PyMT tumors, integrin α11 co-localized strongly with PDGFRβ, and surprisingly, 
poorly with αSMA, PDGFRα, NG2, FAP, and FSP1 [142]. The link between PDGFRβ and 
integrin α11 described by Primac et al. is indeed intriguing, but unexpectedly, integrin α11-
deficiency did not influence the amount of PDGFRβ in the TNBC xenografts in paper II. 
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Noteworthy, the lack of co-expression of integrin α11 with NG2 in breast cancer [142], has 
also been found in PDAC [81], and indicates that integrin α11 is not expressed on pericytes 
in those experimental systems. 
Fibroblasts with a myofibroblastic phenotype share similar functions in fibrosis and in the 
TME, and so far αSMA has been the most commonly used myofibroblast marker. However, 
αSMA is an inconsistent myofibroblast marker in fibrosis [158], and integrin α11β1 has 
emerged as a new receptor that can identify at least a subset of myofibroblasts in wound 
healing [78], fibrosis [79,159] and in the TME (paper II and III, [75,81,86,142,152]). In 
the TME, myofibroblastic CAFs (myCAFs) are poorly defined and their function compared 
to other CAFs is still not fully understood. Surprisingly, seminal papers in the field of CAF 
heterogeneity have demonstrated that myCAFs expressing high αSMA and located 
peritumorally seem to be associated with tumor-suppressive functions in PDAC [31-33]. 
Costa et al. identified two αSMA-positive subsets in human breast cancer, where one of 
these subsets (CAFS1) showed similar characteristics to myCAFs in PDAC as they 
expressed both αSMA and FAP and had predominantly peritumoral localization [34]. 
However, in contrast to myCAFs in PDAC, this CAF subset was demonstrated to be 
immunosuppressive and a potential candidate for CAF-targeted therapy. Of note, integrin 
α11 was found to be strongly expressed in the peritumoral area (paper III, [142]) and co-
localized with αSMA (paper II and III), and it would be of high interest to investigate the 
expression of integrin α11 in relation to the CAF subsets defined by Costa et al. In another 
study of breast CAF heterogeneity, four different CAF subsets have been identified in late 
stage of murine PyMT tumors; matrix CAFs, vascular CAFs, cell cycle CAFs and 
developmental CAFs [21]. Here, αSMA and FAP were expressed in all subsets, and not 
surprisingly, integrin α11 was mostly expressed in matrix CAFs, but also to some degree 
in dCAFs and vCAFs (personal communication, Kristian Pietras, Lund University, 
Sweden). Thus, also among myCAFs the heterogeneity seems so be substantial, not only 
between PDAC and breast cancer, but also within different breast cancer stages and 
subtypes.  
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Given the contrasting reports regarding CAF function in breast cancer, it will be of interest 
to further explore different functional subtypes of CAFs. First, to investigate if these can 
be identified by a more detailed characterization by simultaneous staining of integrin α11 
with other markers. Second, to investigate the impact of their spatial localization within the 
tissue sections. With this in mind, inclusion of anti-integrin α11 antibody in mulitiplexed 
immunostaining or imaging mass cytometry will allow simultaneous comparison of the 
expression of integrin α11 with multiple other CAF markers.  
Stromal integrin α11-deficiency reduces interstitial fluid pressure and alters collagen 
structure 
The progressive changes in the TME during tumor development lead to markedly increased 
PIF in most solid tumors [53,54]. Abnormal blood and lymphatic vessels are well-
recognized features and contribute to elevated tumor PIF, but also contractile fibroblasts 
and a dense ECM have been proposed to modify PIF [50]. Interestingly, in paper II, we 
demonstrated that stromal integrin α11-deficiency decreased PIF in two different implanted 
TNBC xenografts, suggesting a role for integrin α11β1 in the regulation of breast tumor 
PIF. In spheroids composed of only fibroblasts and breast cancer cells, we further showed 
that this effect was mediated, at least partly, by integrin α11-positive fibroblasts. The role 
of integrin α11β1 in regulation of tumor PIF has later also been demonstrated in implanted 
murine E0771 breast tumors (Reed/Stuhr et al., in preparation). These results are in 
agreement with the model for dynamic control of transcapillary fluid flow and PIF proposed 
by Reed et al. [160]. Here, fibroblasts exert a tension on the collagen network through 
collagen-binding integrins which limits swelling of underhydrated ECM. Increased fluid 
flux caused by dysfunctional vasculature may therefore result in increased PIF in solid 
tumors. In support of this, previous studies have shown that transcapillary fluid flow is 
dependent on collagen-binding integrins [87,89,90,161-163]. Integrin α11β1 overexpressed 
in the breast TME may therefore contribute to the regulation of tumor PIF through binding 
to and promoting contraction of the complex collagen network.  
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Structural and physical properties of the ECM have been shown to be essential in breast 
tumorigenesis, where abundance and linearization of fibrillar collagen, and also increased 
tissue stiffness, promote breast tumor progression and are associated with poor outcome 
[45,47,49,164]. Integrin α11β1 has been proposed to influence tumor progression through 
altered regulation and organization of the ECM since ablation of integrin α11 has reduced 
the amount of collagen and collagen fiber organization [86,142]. We found that integrin 
α11-deficiency led to thinner (paper I and II) and more disorganized (paper II) collagen 
fibrils, and several studies have demonstrated an association between collagen fibril 
diameter and PIF. Thinner collagen fibrils seem to be linked to a decrease in tumor PIF 
(paper II, [165,166]), while thicker collagen fibrils associate with increased tumor PIF 
[167,168]. Structural changes in the ECM are likely to influence the fluid transport through 
the TME and thereby PIF, but further studies are needed to show if there are causative 
effects of collagen fibril structure on tumor PIF. Of note, other possible roles of integrin 
α11β1 in the regulation of tumor PIF, such as influence on tumor vasculature, capillary 
permeability, and lymphatic vessels, are not investigated in this thesis, and could indeed be 
explored in future studies. Furthermore, collagen fiber structure beyond what we can see 
from electron microscopy has not been investigated in this thesis. 
Increased tumor PIF reduces convection-driven transport of fluid into and within the tumor 
and can therefore cause insufficient penetration and distribution of anti-neoplastic drugs 
[169]. However, in paper II, reduced tumor PIF by integrin α11-deficiency did not affect 
the uptake of the low-molecular weight drug, 3H-5FU, into MDA-MB-231 tumors. Of note, 
measurements of drug uptake with microdialysis can be technically difficult as it can lead 
to decreased recovery, inflammation, and bleeding. Therefore, it could be of interest to 




Integrin α11 is expressed in a subset of breast myoepithelial cells 
Intriguingly, integrin α11 was also found to be expressed in a subset of breast 
myoepithelium, predominantly in DCIS-associated myoepithelial cells where it co-
localized with αSMA and CK14 (paper III). Myoepithelial cells, separated from the stroma 
by the basement membrane, are in normal circumstances not in contact with collagen I, 
which is the known ligand for integrin α11β1. The expression of integrin α11β1 in 
myoepithelium is therefore surprising, and one central issue concerns the ligand for integrin 
α11β1 in breast myoepithelium. Further studies should elucidate if myoepithelial integrin 
α11β1 binds to components of the basement membrane such as collagen IV. If not, 
upregulation of integrin α11β1 expression in breast myoepithelium could be an early sign 
of myoepithelial contact with collagen in the tumor stroma (which would indicate 
dissociation of the basement membrane). The myoepithelium observed was DCIS-
associated myoepithelium or myoepithelium in relation to benign ducts at the border of the 
breast cancer samples (paper III). In other studies, integrin α11β1 expression seems to be 
low or absent in normal tissues, including normal breast tissue, although a limited number 
of sections have been investigated [81,142]. The expression and function of integrin α11β1 
in myoepithelium in normal breast tissue, in DCIS and in the transition to invasive breast 
cancer should indeed be further explored. Of note, engraftment of breast cancer cell lines 
into mice, which has been performed in paper I and II, represents late stage of primary 
tumor growth. This model bypasses the early stages of breast cancer development where 
myoepithelium has been shown to play a part and is therefore not optimal for investigation 
of breast myoepitheilium.  
Heterogeneity across different models 
Although integrin α11-positive CAFs in experimental breast cancer seem to exert a tumor-
promoting function and to contribute to an increased tumor PIF and collagen organization 
(paper II, [142]), such effects of integrin α11β1 have not been found in all pre-clinical 
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models, and in the 4T1 model (paper I) only minor effects of integrin α11-deficiency was 
seen. As previously mentioned, CAFs seems to display significant heterogeneity across 
different murine TNBC tumors, and to display temporal heterogeneity during tumor 
progression, which may lead to different results when studying CAFs in different pre-
clinical models. As such, the discrepancies in the pre-clinical studies regarding integrin 
α11β1 (paper I and II, [142]) are most likely linked to differences in methodology, such 
as different breast cancer cell lines and different species, in addition to breast cancer 
subtypes and stages. Further studies are therefore needed to elucidate integrin α11β1’s role 
in different breast cancer subtypes and stages using different pre-clinical models.  
Furthermore, the effect of genetic ablation of integrins in mouse models has shown 
conflicting results. For example, integrin αvβ3 has in some, but not all, pre-clinical models 
been shown to increase tumor PIF and collagen fibril diameter, increase tumor angiogenesis 
and stimulate tumorigenesis [170,171]. Compensatory mechanisms and overlapping 
functions are common features for integrins [171]. As recently reported, the effect of 
integrin α11 inhibition on collagen contraction and CAF migration is greater in the absence 
of other collagen receptors, and smaller than the effect of inhibition of β1 integrin, 
indicating that not only other collagen-binding integrins, but also other β1 integrins, partly 
overlap with integrin α11β1’s function [81]. Especially, integrin α11β1 shows functional 
resemblances to the collagen-binding integrin α2β1 as both integrins are responsible for 
fibroblast-collagen interactions [65]. However, the role of integrin α2β1 in tumorigenesis 
has been difficult to dissect because of its wide expression [65]. In breast cancer, integrin 
α2β1 is actually downregulated and ablation in mice seems to increase breast cancer 
metastasis [10,172]. With this in mind, studies should aim to not only explore the co-
expression and function of integrin α11β1 in relation to other CAF markers, but also in 
relation to other integrins.  
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6. Main conclusions 
1: Using integrin α11-KO mice, we found that integrin α11-deficiency lead to reduced 
tumor PIF with two of three breast cancer cell lines tested. Further, changes in collagen 
fibril structure were observed in all orthotopic breast cancer models and growth of MDA-
MB-231 breast cancer cells was inhibited in α11-KO compared to WT mice. Thus, stromal 
integrin α11β1 seems to contribute to high tumor PIF, collagen fibril organization and may 
also stimulate experimental breast cancer growth in vivo although this was not consistent 
in all pre-clinical models.  
2: We have established conditions for reproducible and specific staining of integrin α11 in 
FFPE human tumor material using a new antibody against the integrin α11 subunit. 
3: Integrin α11 was found to be expressed in stromal spindle-shaped cells compatible with 
CAFs in the breast TME. Additionally, integrin α11 was expressed on a subset of breast 
myoepithelial cells. Further, strong stromal integrin α11 expression was associated with 
aggressive breast cancer features, but not with breast cancer specific survival.   
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7. Future perspectives 
We and others have over the last decade demonstrated that integrin α11β1 is highly 
expressed in the breast cancer stroma, and that it seems to be involved in breast tumor PIF 
regulation, collagen organization and have a promoting role in breast cancer progression. 
However, many questions remain regarding the role of integrin α11β1 in breast cancer. 
Further investigation of integrin α11-positive cells in the breast TME should continue in 
different breast cancer subtypes and stages.  
First, integrin α11β1 should be included in studies aiming to further characterize 
functionally distinct CAF subsets. Second, it will be intriguing to dissect the spindle-shaped 
cell population positive for integrin α11β1 in the breast TME and to investigate if integrin 
α11β1 additionally is expressed on other cell types than merely CAFs. With this in mind, 
investigation of the expression of integrin α11β1 in regard to other markers and their spatial 
localization will be of importance, and this will be possible by including anti-integrin α11 
antibodies in multiplexed IHC or imaging mass cytometry. Our new antibodies against 
human integrin α11 will also enable cell sorting and thereby closer characterization of 
integrin α11-expressing cells with for example single cell sequencing. Furthermore, 
isolation of integrin α11-positive cells and functional studies are necessary to gain further 
mechanistic insight into the role of integrin α11β1 in breast cancer.  
Although integrin α11β1 currently does not seem to have a clear role as a prognostic marker 
alone based on the results on breast cancer in this thesis, these data should be confirmed in 
other breast cancer cohorts, and the prognostic value of integrin α11β1 in combination with 
other markers should be investigated. 
In the future, sophisticated mouse models will hopefully be valuable tools used to further 
investigate integrin α11β1’s role in breast cancer. Especially, conditional α11-KO mice, in 
which the knockout of integrin α11 can be spatially and temporally regulated, would 
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provide important information of the isolated effect of integrin α11β1 in different cell types 
and at different times.  
Also, further investigation of the mechanism behind how integrin α11β1 contribute to the 
regulation of tumor PIF is needed, and other models for drug uptake should be performed.  
Finally, both in vitro and in vivo experiments should aim to investigate the function of 
integrin α11β1 in breast myoepithelium, in addition to careful characterization of the 
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It has been implied that the collagen binding integrin α11β1 plays a role in carcinogenesis.
As still relatively little is known about how the stromal integrin α11β1 affects different
aspects of tumor development, we wanted to examine the direct effects on primary tumor
growth, fibrosis, tumor interstitial fluid pressure (PIF) and metastasis in murine 4T1 mam-
mary and RM11 prostate tumors, using an in vivo SCID integrin α11-deficient mouse model.
Methods
Tumor growth was measured using a caliper, PIF by the wick-in-needle technique, activated
fibroblasts by α-SMA immunofluorescence staining and fibrosis by transmission electron
microscopy and picrosirius-red staining. Metastases were evaluated using hematoxylin and
eosin stained sections.
Results
RM11 tumor growth was significantly reduced in the SCID integrin α11-deficient (α11-KO)
compared to in SCID integrin α11 wild type (WT) mice, whereas there was no similar effect
in the 4T1 tumor model. The 4T1 model demonstrated an alteration in collagen fibril diame-
ter in the integrin α11-KO mice compared to WT, which was not found in the RM11 model.
There were no significant differences in the amount of activated fibroblasts, total collagen
content, collagen organization or PIF in the tumors in integrin α11-deficient mice compared
to WTmice. There was also no difference in lung metastases between the two groups.
Conclusion
Deficiency of stromal integrin α11β1 showed different effects on tumor growth and collagen
fibril diameter depending on tumor type, but no effect on tumor PIF or development of lung
metastasis.
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Introduction
Carcinomas consist of both malignant cells and stroma, the latter being composed of extracel-
lular matrix (ECM) molecules and associated cells [1]. The main focus of cancer research has
traditionally been on tumor cell alterations, but in the last decade ECM has been identified as
an important contributor to tumor development and progression [2, 3]. Tumor cells release
growth factors and proteolytic enzymes that modulate the stroma [4, 5], and the stromal com-
ponents interact with the tumor cells in a reciprocal manner to regulate different aspects of
tumor development [1].
Integrins belong to a family of major cell surface receptors that mainly bind ECM proteins.
Twenty-four different integrins, forming heterodimers by combining 18 α- and 8 β-subunits,
have been identified. The integrins mediate cell-cell and cell-matrix adhesion and are capable
of cell inside-out and outside-in signaling [6, 7]. Their role on the surface of tumor cells has
been extensively studied, and integrins contribute to proliferation, migration and survival of
malignant cells, and have thus been suggested to play an important role in tumor progression
[8]. Altered integrin expression in several stromal cells, including the cancer associated fibro-
blasts, may also influence tumor growth and progression [8–10], and the present study focuses
on the effect of the collagen binding integrin α11β1 in the tumor stroma.
The integrin subunit α11 forms a heterodimer with integrin subunit β1 and is one of four
collagen-binding integrins [11]. In mouse embryos, integrin α11β1 is a major collagen receptor
on a subset of fibroblasts [12], but characterization of its expression in adult and human tissue
is still insufficient [13]. Integrin α11β1 has high affinity for collagen type I, and has been indi-
cated to be involved in cell migration and collagen reorganization [10, 14, 15], but other than
this, there is limited knowledge about α11β1’s normal physiological role.
Integrin α11 has also been implicated to play a role in carcinogenesis. Integrin α11 is
expressed in metastases from human malignant melanoma [16], and in stromal fibroblasts in
human non-small-cell lung cancer (NSCLC) [9, 17]. It has also been shown, both in vitro and
in vivo, that α11 integrin expressed on fibroblasts may stimulate the growth of tumor cells [9,
10, 18]. Earlier findings have indicated that stromal integrin α11 has a role in both primary
tumor growth and in the metastatic process [9, 10], and this has raised the question if integrin
α11 could be used as a biomarker, or if targeting integrin α11 could prove to be a novel
approach in cancer treatment.
Since still relatively little is known about how the stromal integrin α11β1 in tumors affects
different aspects of tumor development, we decided to examine the direct effects of integrin
α11β1 on primary tumor growth, fibrosis, tumor interstitial fluid pressure and metastasis in a
4T1 mammary tumor- and a RM11 prostate tumor model.
Methods
Cell Lines
The murine mammary carcinoma cell line 4T1 was obtained from the American Type Culture
Collection (Manassas, VA., USA). The prostate cell line RM11 was a gift from Associate profes-
sor Thomas S. Griffith (University of Minnesota, Minneapolis, MN., USA). This cell line was
originally derived from a ras/myc reconstituted tumor in a Balb/c mouse [19]. The cells were
grown in RPMI-1640 medium (HEPES solution for RM11 cells) supplemented with 10% Foetal
Bovine Serum (Sigma-Aldrich, Steinheim, Germany), 100 units/ml penicillin, 100 μg/ml strep-
tomycin, 1–2% L-glutamine (all from Sigma-Aldrich, Steinheim, Germany), with an addition
of 1% sodium pyruvate for the RM11 cells. All cells were grown as single monolayers in a
humidified incubator at 37°C in 5% CO2 and they were seeded and used at log phase in all
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experiments. SV40 transformed wild type MEF cell line [12] was cultured in DMEM (Sigma-
Aldrich, Steinheim, Germany), 10% Foetal Bovine Serum and 100 units/ml penicillin, 100 μg/
ml streptomycin as previosly described.
Animal Model
The integrin α11-deficient heterozygous SCID mouse strain was generated as described [10].
The mice were bred heterozygously, and SCID integrin α11 wild type (WT) and SCID integrin
α11-deficient (α11-KO) offsprings were used in the experiments. PCR-genotyping was per-
formed on DNA extracted from ear biopsies as previously described [20]. Female mice were
used for the mammary 4T1 tumor model and male mice for the prostate RM11 tumor model.
The animals were kept in individually ventilated cages and cared for regularly. Efforts were
made to age- and weight match the animals. The animal experiments were approved by the
local ethical committee at The Laboratory Animal Facility, the Department of Clinical Medi-
cine, the Faculty of Medicine and Dentistry, University of Bergen (Permit Number 20135571).
All experiments were performed in accordance with the regulations of the Norwegian Animal
Research Authority.
Establishing Tumors
A total of 1 x 106 4T1 tumor cells in 0.15 ml PBS were injected into the fourth mammary fat
pads on each side. 3 x 105 RM11 cells were injected subcutaneously on both sides of the mouse
flank. The 4T1 tumors were measured using a caliper on days 7, 10, 13, 16 and endpoint 18
post injection, but some were ended day 17 due to rapid tumor growth. The RM11 tumors
were measured using a caliper on days 9, 11 and endpoint day 13 post injection. All experi-
ments were performed blinded to genotype. The tumor volume was calculated using the for-
mula; tumor volume (mm3) = (π/6) x a2 x b, where a represents the shortest diameter and b
represents the longest diameter of the tumor. All animals were anesthetized using Isofluran
(Isoba1vet. 100%, Schering-Plough A/S, Farum, Denmark) and were sacrificed by cervical dis-
location under anesthesia.
Measurement of Interstitial Fluid Pressure
The tumor interstitial fluid pressure (PIF) was measured using the wick-in-needle technique
[21]. Briefly, a standard 23-gauge needle with a side hole filled with nylon floss and saline was
inserted into the central part of the tumor after calibration and connected to a PE-50 catheter,
a pressure transducer and a computer for pressure registrations, using the software Powerlab
chart (version 5, PowerLAb/ssp ADinstruments, Dunedin, New Zealand). After a period of sta-
ble pressure measurements, the fluid communication was tested by clamping the catheter
which shall cause a transient rise and fall in pressure. Measurements were accepted if the pre-
to post-clamping value was within ± 1 mmHg.
Electron Microscopy of Collagen Fibrils in the Tumor
A JEM-1230 Transmission Electron Microscope (TEM) (Jeol, Tokyo, Japan) was used to mea-
sure the diameter of the collagen fibrils. The tissue samples were cut into approximately 1x1x1
mm samples and fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer, and then washed in
PBS. The samples were post-fixed in 1% OsO4 in PBS and dehydrated in increasing concentra-
tions of ethanol (70%, 95% and 100%), and then propylenoxide, before being embedded in
Agar 100 Resin and sectioned at 60 nm. Four to five images from different areas of the tissue
were captured at x100 000 magnification and analyzed using Image J 1.46 (National Institute
Integrin α11β1 and Tumor Growth
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of Health, Beteshda, MD., USA). Because of uneven distribution of collagen in the tissue, the
images were taken from the areas of the tissue where collagen was found.
A Jeol JSM-7400F Scanning Electron microscope (SEM) was used to study the tumor colla-
gen scaffold architecture. The tumors were cut in 1x1x1 mm samples and fixed in 2.5% glutar-
aldehyde in 0.1 M phosphate buffer, before being placed in 10% NaOH for 7 days with
replacement every day. The samples were thereafter placed in tap-water for 2–4 days and then
dehydrated in increasing concentrations of ethanol (70%, 95% and 100%), and dried in a “criti-
cal point-dryer”. The tumor tissue was mounted on an Au-stub and coated with a 10 nm layer
of gold and palladium using a Jeol JFC-2300HR High Resolution fine coater. Five images from
different areas of the tumor were captured from each tumor at x10 000 magnification.
Protein Extraction andWestern Blot Analysis
The protein expression of integrin α11 in tumors lysates and cultured tumor cell lines was
investigated. Tumor samples and cultured cell lines were lysed in buffer containing 50 mM
Tris-HCl, pH 7.4, 150 mMNaCl and 1% Triton X supplemented with one tablet of protease
inhibitor cocktail (complete EDTA-free; Roche Diagnostics GMBh, Mannheim, Germany) per
10 ml buffer. After homogenization, tumor samples were centrifuged for 10 min at 12 000 rpm
and protein concentration was measured using PierceTM BCA Protein Assay Kit (Life Technol-
ogies, Thermo Fisher Scientific, Waltham, MA., USA) according to the manufacturer’s proto-
col. For western blot analysis cell lines were grown to confluency in 6 well plates washed with
cold PBS, lysed and scraped with cell scraper on ice. Cell lysates were centifuged at 13 000 rpm
for 30 min at +4° C, and supernatant harvested. Protein lysates were loaded in XT Sample
Buffer, 4X (Bio-Rad Laboratories, Inc, Hercules, CA., USA) containing 50 mMDL-Dithiothrei-
tol (dTT) (Sigma-Aldrich, Steinheim, Germany), and run through a 10% PreciseTM Protein
Gel (Life Technologies, Thermo Fisher Scientific). The proteins were then transferred to a
nitrocellulose membrane using InvitrogenTM iBlot1 Dry Blotting System (Life Technologies,
Thermo Fisher Scientific) and an iBlot1 Transfer Stack (Life Technologies, Thermo Fisher
Scientific). After blocking in I-block (Life Technologies, Thermo Fisher Scientific) for 1 hour at
room temperature, the membranes were incubated over-night with rabbit polyclonal anti-
mouse α11 antiserum [22] 1:500 in I-block at +4°C. The anti-mouse α11 antiserum is produced
against the peptide CRREPGLDPTPKVLE from the integrin α11 cytoplasmic domain (Innova-
gen AB, Lund, Sweden) [22]. This was followed by incubation with a HRP-coupled secondary
antibody (goat anti-rabbit; AB97051, Abcam, Cambridge, UK; 1:5000 in TBS-T). The bands
were visualized by the ECL system PierceTM ECLWestern Blotting Substrate (Life Technolo-
gies, Thermo Fisher Scientific). The membrane was then re-probed with β-actin antibody
(AB8227, Abcam; 1:5000 in I-block) and HRP-coupled secondary antibody (goat anti-rabbit;
AB97051, Abcam; 1:5000 in TBS-T). Membranes were visualized using the Gel ChemiDoc sys-
tem and Quantity One 4.6.6 imaging software (Bio-Rad Laboratories, Inc, Hercules, CA.,
USA).
Picrosirius-Red and Immunofluorescence Staining
For a semi-quantitative measurement of collagen type I and III, picrosirius-red stain (Poly-
sciences inc, Warrington, FL., USA) was used. Five paraffin embedded tumor sections with a
thickness of 5μ from each group were deparaffinized, stained in picrosirius-red for one hour,
dehydrated and mounted. Five to six images from each tumor were captured with x10 magnifi-
cation (Nikon Digital Sight, Nikon Corporation, Tokyo, Japan).
For α-SMA staining, FITC-conjugated monoclonal anti-actin α-smooth muscle antibody
(F3777, dilution 1:200, Sigma Aldrich, Steinheim, Germany) was used. Five paraffin embedded
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tumor sections with a thickness of 10μ from each group were stained. Prior to staining, the sec-
tions were first deparaffinized, and then placed in citrate buffer for 25 minutes in 95°C. Non-
specific background staining was reduced by adding 0.3% hydrogen peroxide in methanol to
the sections. Five images from each tumor were captured with x20 magnification with an Axio-
scope fluorescence microscope and a digital AxiocamMRm camera (Zeiss, Oberkochen,
Germany).
To identify the amount of pixels positive for picrosirius-red staining and α-SMA, the soft-
ware Image J (National Institute of Health, Beteshda, MD., USA) was used. Individual thresh-
old values were set for each image to adjust for differences in intensity and background. For
both stainings, images were taken in an organized pattern in the tumor periphery in order to
avoid the necrotic central area.
Metastasis
To allow development of metastasis, female animals were injected with 3 x 105 4T1 cells in
their right, fifth mammary fat pad. The experiment was ended on day 21 due to animal welfare.
The lungs were fixed using approximately 1 ml of Bouin’s solution (Gurr BDH Chemicals Ltd,
Poole, UK) injected into the trachea. Then the lungs were dissected out, fixed in new Bouin’s
solution and washed in 70% ethanol before dehydration. Immediately following this procedure,
the liver and brain were harvested and fixed in formalin. All tissues were embedded in paraffin
using standard procedures, sectioned, and stained with hematoxylin and eosin (H & E). To
quantify lung metastasis, three coronal sections, 600 μm apart and covering both lungs, were
examined for each animal. The number of metastases per section was counted and total area
covered by metastases was measured (Nikon Digital Sight, Nikon Corporation, Tokyo, Japan).
Statistical Analysis
For statistical analysis, Sigmaplot 12.5 (Systat Software Inc., Chicago, IL., USA) and Graph Pad
Prism 6 (GraphPad Software, Inc., La Jolla, CA., USA) were used. Either the unpaired two-
tailed t-test or the Mann UWhitney t-test, were used to analyze statistical differences between
the two groups. For analysis of tumor growth, t-test with Welch correction was used. The mice
injected with 4T1 cells were sacrificed at either day 17 or day 18, and the tumors harvested on
the same day were tested against each other. Results were accepted as statistically different
when p< 0.05. Graph Pad Prism 6 was used to create all figures. Data is given as mean ± SD,
and number of measurements (n) refers to number of tumors unless otherwise specified.
Results
Integrin α11 Expression
Using western blotting, integrin α11 was found to be expressed in tumor lysates from both 4T1
and RM11 tumors grown in WTmice, whereas no integrin α11 was detected in the tumors
grown in α11-KO mice (Fig 1). No integrin α11 expression was detected in lysates from cul-
tured 4T1 and RM11 tumor cells (Fig 1).
Tumor Growth
The tumor volume of RM11 prostate tumors grown subcutaneously were significantly impeded
(p< 0.04 and 0.02) in tumors grown in α11-KO mice compared to tumors grown in WT mice
during their 13 day growth period, whereas 4T1 mammary tumors did not show any difference
in tumor growth between α11-KO mice and WTmice when comparing tumors that were
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harvested on the same day (17 or 18) (Fig 2). All end-point measurements in the 4T1 tumor
model are summarized at day 17 in Fig 2.
α-Smooth Muscle Actin (α-SMA) Expression
α-SMA immunofluorescent stained tumor sections were used to quantify the relative amount
of activated fibroblasts in the tumors (represented by pixels). There was no significant differ-
ence in the level of α-SMA expression in the 4T1 or the RM11 tumors grown in α11-KO mice
compared to that in WT mice (Fig 3).
Tumor Collagen Structure
In the present study collagen structure in the α11-KO versus WT tumors was compared by
measuring the collagen fibril diameters using transmission electron microsopy (TEM) analyses.
An uneven distribution of fibril diameter was found, leading to a shift towards thinner collagen
fibrils in 4T1 carcinomas grown in α11-KO mice compared to WT (Fig 4A). The average colla-
gen diameter in the 4T1 tumors grown in α11-KO mice (37.2 ± 1.5 nm) was significantly
smaller (p< 0.006) than in WTmice (50.4 ± 3.0 nm) (Fig 4B). In the RM11 tumors there was
no such difference in the collagen diameter between the tumors grown in α11-KO andWT
mice (Fig 4D). To evaluate whether the decreased collagen fibril diameter was a more general
feature in the α11-KO mice and not only tumor specific, collagen fibril diameter in dermis
Fig 1. The integrin α11 expression in 4T1 (A) and RM11 (B) cultured tumor cells and tumor lysates from
tumors in SCID integrin α11 wild type (+/+) and SCID integrin α11-deficient (-/-) mice. Positive control is a
SV40 transformed wildtype mouse embryonic fibroblast cell line (MEF).
doi:10.1371/journal.pone.0151663.g001
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from healthy male mice was evaluated. In dermis, no difference in the collagen diameter
between α11-KO and WTmice was found.
Scanning electron microscopy (SEM) did not show any difference in collagen architecture
between the α11-KO andWT neither in the 4T1 tumors nor the RM11 tumors (Fig 5).
Tumor Collagen Amount
Picrosirius-red staining was used to quantify the most abundant collagens; type I and III, in the
tumor sections. No significant difference in the amount of collagen was seen in the 4T1 and the
RM11 tumors grown in α11-KO compared to those grown in WTmice (Fig 6).
Tumor Interstitial Fluid Pressure (PIF)
Tumor PIF was determined using the wick-in-needle technique. There was no significant dif-
ference in PIF in either 4T1 or RM11 tumors grown in α11-KO versus WT mice (Fig 7).
Tumor Metastases
To evaluate whether stromal integrin α11 has an effect on metastatic potential, H & E stained
sections from the 4T1 metastatic model were used. The 4T1 breasts cancer cell line is known to
metastasize to lungs, liver, bone and brain [23]. Excessive macroscopic surface metastases were
observed in all lungs. There was no difference in the 4T1 tumor cells ability to metastasize to
the lungs in the α11-KO mice compared to the WTmice investigated at day 21 post injection
(Fig 8). Metastases were also observed in the livers. In addition, the livers were significantly
infiltrated by isles of extramedullary hematopoiesis, thereby making it difficult to quantify
these metastases. Hence, the liver metastases were not further evaluated. No metastases were
found in the brain of any of the animals at endpoint day 21.
Fig 2. The growth of 4T1 (A) and RM11 (B) tumors in SCID integrin α11 wild type (WT) and SCID integrin α11-deficient (α11-KO) mice. A total of 1 x 106 4T1
and 3 x 105 RM11 cells were injected into the mammary fat pad and subcutaneously in the mouse flank, respectively. Endpoint values in the 4T1 model
include tumors that were harvested on days 17 and 18. Mean ± SEM. * p < 0.04, ** p < 0.02.
doi:10.1371/journal.pone.0151663.g002
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Discussion
Stromal integrin α11β1 has been implicated to play a role in experimental non-small-cell lung
cancer (NSCLC) carcinogenesis [9, 10], and is expressed in human lung cancer [9, 17, 24] and
in metastasis from human malignant melanoma [16]. However, the role of integrin α11β1 in
other cancer types remains to be elucidated.
The present study showed that the primary tumor growth of RM11 prostate tumors was
reduced in α11-deficient mice compared with WTmice, however, this was not the case in 4T1
mammary tumors. Furthermore, there was a shift towards thinner collagen fibrils in the 4T1
tumors grown in α11-deficient mice. In spite of altered collagen fibrils, there were no differ-
ences in the amount of activated fibroblasts, total collagen content, collagen organization or
PIF in the tumors. In addition, the metastatic potential to the lung of 4T1 tumors was not
affected by stromal α11-deficiency.
In this study we examined the role of integrin α11 in tumor stroma. Following injection of
tumor cells in both WT and α11-KO mice, the implanted tumor cells derive their stroma from
the host animal, and hence the tumors in α11-KO mice will have stroma that is deficient in
integrin α11. Differences in tumor development can be presumed to be due to differences in
tumor stroma between the two groups since the tumor cells injected are the same. As seen in
Fig 3. Percentage of pixels positive for α-SMA in 4T1 (n = 5) and RM11 (n = 5) tumors from SCID integrin α11 wild type (WT) and SCID integrin α11-deficient
(α11-KO) mice were calculated from immunofluorescent images (A, D). No statistical differences in 4T1 (p = 0.62) or RM11 (p = 0.40) tumors were found
using unpaired two-tailed t-test. Mean ± SD. Representative images of α-SMA-staining (green) from both genotypes in 4T1 (B, C) and RM11 (E, F) tumors
are shown. Scale bars indicate 50 μm.
doi:10.1371/journal.pone.0151663.g003
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Fig 4. Collagen fibrils were analyzed using transmission electron microscopy (TEM).Collagen fibril
diameter distribution and average fibril diameter per tumor in 4T1 (n = 7 and n = 5) tumors (A, B), showed a
shift towards thinner fibrils in SCID integrin α11-deficient (α11-KO) mice. RM11 tumors (n = 4 and n = 3) (C,
D) and dermis (n = 4 and n = 3) (E, F) showed no significant differences in average collagen fibril diameter in
SCID integrin α11 wild type (WT) and SCID integrin α11-deficient (α11-KO) mice (RM11 p = 0.20, dermis
Integrin α11β1 and Tumor Growth
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Fig 1, we find that integrin α11 is expressed in tumors grown in WTmice, but not in the
tumors grown in α11-KO mice.
There are only two previous in vivo studies concerning tumor growth and stromal integrin
α11-deficiency, and they both showed a stimulatory effect of integrin α11 on tumor growth [9,
10]. First, wildtype mouse embryonic fibroblasts (MEFs) were found to have a greater stimulat-
ing effect on the growth of human NSCLC cells than MEFs lacking integrin α11 when co-
p = 0.47) using unpaired two-tailed t-test. Mean ± SD. * p < 0.006. Representative TEM images of collagen
fibrils from both genotypes in 4T1 tumors (G, H), RM11 tumors (I, J) and dermis (K, L) are shown. Scale bars
indicate 0.2 μm.
doi:10.1371/journal.pone.0151663.g004
Fig 5. A representative scanning electron micrograph of collagen in 4T1 tumors (n = 3) from SCID integrin α11 wild type (WT) (A) and SCID integrin
α11-deficient (α11-KO) (B) and RM11 tumors (n = 3) fromWT (C) and α11-KOmice (D), respectively. Scale bars indicate 1 μm.
doi:10.1371/journal.pone.0151663.g005
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injected in mice together with tumor cells [9]. Second, in a recent study by Navab et al.,
reduced tumor growth in α11-KO mice was described using subcutaneously implanted NSCLC
xenografts [10]. In addition, in an in vitro heterospheroid model, Lu et al. showed that human
lung cancer cells grown with WT fibroblasts had a higher tendency to proliferate and migrate
compared to tumor cells grown with fibroblasts deficient in integrin α11 [18]. Taken together,
these studies indicate that α11 integrin on fibroblasts interact with tumor cells and can play a
role in regulating tumor growth. Nevertheless, in the present study we only found an effect on
tumor growth in the subcutaneously implanted RM11 tumor model, and not in the orthotopi-
cally implanted 4T1 tumor model. It is not known whether these effects are tumor-type spe-
cific, or if other factors such as the location of tumor implantation, is of importance.
Integrin α11 is a collagen-binding integrin, and has previously been shown to play a role in
collagen reorganization both in vitro and in vivo [10, 14, 15]. In this study we found that the
collagen fibrils in the 4T1 tumors grown in integrin α11-deficient mice were thinner than
those in tumors grown in WTmice. However, this finding was not universal, since the RM11
tumors showed no difference in collagen fibril diameter. A recent study on wound healing also
found an increase in thinner collagen fibrils in the granulation tissue from integrin α11-defi-
cient mice [25]. Furthermore, the study demonstrated that α11-deficiency resulted in reduced
Fig 6. The total fraction of picrosirius-red staining quantified in 4T1 (n = 5) and RM11 (n = 5 and n = 3) tumors in SCID integrin α11 wild type (WT) and SCID
integrin α11-deficient (α11-KO) (A, D). No statistical differences in 4T1 (p = 0.82) or RM11 (p = 0.37) tumors were found using unpaired two-tailed t-test.
Mean ± SD. Representative images of picrosirius-red staining from both genotypes in 4T1 (B, C) and RM11 (E, F) tumors are shown. Scale bars indicate
100 μm.
doi:10.1371/journal.pone.0151663.g006
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formation of granulation tissue and impaired wound contraction [25]. As tumors can be
looked upon as “wounds that do not heal” and involve many of the same processes [26], this
could represent an interesting parallel to the present study. It is somewhat surprising that in
the current study the shift towards thinner collagen fibrils only was seen in the 4T1 model, in
which there was no effect of integrin α11 deficiency on tumor growth, whereas no alteration in
collagen fibrils was seen in the RM11 tumor model.
Activated fibroblasts play a crucial role in synthesis and remodeling of collagen in tumors
[27, 28]. We found here that the amount of activated fibroblasts, identified by the marker α-
SMA, was the same in tumors grown in α11-deficient mice when compared with WTmice.
This does not correspond to the findings in the study on NSCLC where a decrease in α-SMA
expression in α11-KO xenograft tumors was found compared to in WT xenograft tumors [10].
Moreover, reduced α-SMA expression was found in granulation tissue in integrin α11-deficient
mice compared to WTmice [25]. In addition, also two earlier studies have suggested that integ-
rin α11 stimulates fibroblast differentiation under different conditions [29, 30]. Thus, available
data suggest that integrin α11 may play a role in activation of fibroblasts, although in this study
we did not observe any difference in α-SMA expression in tumors grown in α11-deficient mice
compared to WT mice.
Regarding the amount of collagen in the tumors, there was no significant difference in the
amount of picrosirius-red staining in the 4T1 or the RM11 tumors in the present study. This
does not correspond with the recent study on NSCLC where the amount of fibrillar collagen
was reduced in xenografts in α11-KO compared to WTmice [10].
While we did not observe any difference in collagen organization in 4T1 or RM11 tumors,
neither with SEM nor with picrosirus-red staining, Navab et al [10] found that collagen had a
more non-linearized pattern in NSCLC tumors in α11-KO mice using different approaches,
namely picrosirius-red staining, second harmonic generation imaging and atomic force
Fig 7. The individual interstitial fluid pressures (PIF) in 4T1 (A) and RM11 (B) tumors in SCID integrin α11 wild type (WT) and SCID integrin α11-deficient
(α11-KO) mice. The horizontal lines indicate the mean values. No statistical differences in 4T1 (p = 0.78) or RM11 (p = 0.47) tumors were found using
unpaired two-tailed t-test.
doi:10.1371/journal.pone.0151663.g007
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Fig 8. Histomorphometric quantification of H & E -stained lungs from the 4T1 model from SCID integrin α11 wild type (WT) (n = 4) and SCID integrin
α11-deficient (α11-KO) (n = 5) mice. Average number of metastasis per section (A) and average area per section (B) is shown. The horizontal lines indicate
the mean values. No significant differences were observed (p = 0.73 and p = 0.79) using Mann UWhitney t-test and unpaired two-tailed t-test, respectively. A
representative lung with metastasis from aWTmouse is shown (C, D). Scale bar indicates 100 μm.
doi:10.1371/journal.pone.0151663.g008
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microscopy. It is therefore likely that the role of integrin α11 in collagen organization differs in
the NSCLC tumor model compared to the tumor models that were used in the present study.
Taken together, reduced tumor growth in α11-KO mice, has in an earlier study, been shown
to be concomitant with reduced α-SMA and altered collagen structure in the tumors [10]. The
findings in the present study, however, are different. Stromal α11-deficiency caused reduced
RM11 tumor growth, despite no differences in collagen fibril diameter, collagen amount or α-
SMA expression. In addition, there is a smaller proportion of activated fibroblasts (a-SMA
staining) and collagen in the RM11 tumors than the 4T1 tumors (Figs 3 and 6), and one could
therefore suggest that these stromal factors seem less relevant for RM11 tumor pathogenesis.
Hence, in this study, the difference in tumor growth cannot be associated to changes in fibro-
blast activation or collagen alterations, and the pathogenesis behind the reduced tumor growth
in the present study remains unknown. One can conclude, however, that the present findings
indicate that different tumors seem to show different responses to stromal integrin α11-defi-
ciency, although the mechanisms responsible are at this point not yet known.
One of the common features in the tumor microenvironment is the high interstitial fluid
pressure (PIF), which can hinder efficient delivery of cytostatic drugs across the capillary bar-
rier and into the tumor [31, 32]. Therefore, pharmacologically lowering of PIF can improve
transport of cytostatic drugs [32]. Collagen in tumors has been recognized to be one of the fac-
tors important for tumor PIF [32–34]. Furthermore, two previous studies have shown that
integrin α11 may have a role in regulating PIF in different conditions [15, 18]. It was of interest
for us, therefore, to investigate the effect of stromal α11 deficiency on tumor PIF. In this study
we did not find any difference in PIF between tumors grown in integrin α11-deficient mice
compared to WT mice, indicating that α11 may not be important for PIF regulation in these
tumors. Since collagen content is one of the factors that have been shown to be important for
PIF [32–34], and the present study did not reveal any effect of stromal integrin α11 deficiency
on amount of collagen in the tumors, an unchanged PIF was probably to be expected.
Little is known about how integrin α11 affects tumor metastasis, although there are some find-
ings that indicate that it may play a role in the metastatic process. Integrin α11 mRNA has been
found to be expressed in human metastases frommalignant melanoma and high mRNA levels of
the collagen binding integrins α1, α2 and α11 correlated with poor patient outcome [16].
In the in vivo study by Navab et al., NCI-H460SM lung carcinoma cells formed significantly
less spontaneous metastases in SCID integrin α11-deficient mice compared to SCIDWTmice
[10]. Furthermore, in a heterospheroid in vitromodel it was found that human lung cancer
cells had reduced migratory and invasive capacity when cultured together with integrin
α11-KO fibroblasts compared with WT fibroblasts [18]. Some studies have also indicated that
integrin α11 on cancer cellsmay be important in the metastatic process, such as the study by
Westcott et al where integrin α11 was among the genes highly expressed in a subpopulation of
breast cancer cells with enhanced invasiveness [35]. Furthermore, two separate tumor studies
indicate that integrin α11 RNA is upregulated during epithelial to mesenchymal transition
(EMT) [36, 37].
However, in spite of earlier findings, in the present study we found no indication that there
was a difference in lung metastases of 4T1 tumors grown in the integrin α11-deficient mice
compared to those grown in WTmice, again demonstrating that integrin α11`s role in cancer
development may vary in different tumor models.
Conclusion
The present study showed reduced tumor growth in the α11-deficient mice in the RM11
model, but no effect in the 4T1 model, only partially confirming the suggested role of integrin
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α11 in promoting tumor growth. Even though the present study demonstrated an alteration in
collagen fibril diameter in 4T1 mammary tumors in the α11-deficient mice, it did not confirm
previously shown alterations in collagen amount and organization, or in α-SMA expression.
These discrepancies may be due to differences in tumor model, tumor type, location and
aggressiveness of the tumor type. Our findings clearly show that further investigations regard-
ing the role of integrin α11β1 in different tumor types are needed.
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Stromal integrin α11-deficiency reduces
interstitial fluid pressure and perturbs
collagen structure in triple-negative breast
xenograft tumors
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Abstract
Background: Cancer progression is influenced by a pro-tumorigenic microenvironment. The aberrant tumor stroma
with increased collagen deposition, contractile fibroblasts and dysfunctional vessels has a major impact on the interstitial
fluid pressure (PIF) in most solid tumors. An increased tumor PIF is a barrier to the transport of interstitial fluid into and
within the tumor. Therefore, understanding the mechanisms that regulate pressure homeostasis can lead to new insight
into breast tumor progression, invasion and response to therapy. The collagen binding integrin α11β1 is upregulated
during myofibroblast differentiation and expressed on fibroblasts in the tumor stroma. As a collagen organizer and a
probable link between contractile fibroblasts and the complex collagen network in tumors, integrin α11β1 could be a
potential regulator of tumor PIF.
Methods: We investigated the effect of stromal integrin α11-deficiency on pressure homeostasis, collagen organization
and tumor growth using orthotopic and ectopic triple-negative breast cancer xenografts (MDA-MB-231 and MDA-MB-
468) in wild type and integrin α11-deficient mice. PIF was measured by the wick-in-needle technique, collagen by
Picrosirius Red staining and electron microscopy, and uptake of radioactively labeled 5FU by microdialysis. Further, PIF in
heterospheroids composed of MDA-MB-231 cells and wild type or integrin α11-deficient fibroblasts was measured by
micropuncture.
Results: Stromal integrin α11-deficiency decreased PIF in both the orthotopic breast cancer models. A concomitant
perturbed collagen structure was seen, with fewer aligned and thinner fibrils. Integrin α11-deficiency also impeded
MDA-MB-231 breast tumor growth, but no effect was observed on drug uptake. No effects were seen in the ectopic
model. By investigating the isolated effect of integrin α11-positive fibroblasts on MDA-MB-231 cells in vitro, we provide
evidence that PIF regulation was mediated by integrin α11-positive fibroblasts.
Conclusion: We hereby show the importance of integrin α11β1 in pressure homeostasis in triple-negative breast tumors,
indicating a new role for integrin α11β1 in the tumor microenvironment. Our data suggest that integrin α11β1 has a
pro-tumorigenic effect on triple-negative breast cancer growth in vivo. The significance of the local microenvironment is
shown by the different effects of integrin α11β1 in the orthotopic and ectopic models, underlining the importance of
choosing an appropriate preclinical model.
Keywords: Integrin α11β1, Interstitial fluid pressure, Cancer associated fibroblasts, Collagen organization, Triple-negative
breast cancer
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Background
Triple-negative breast cancer (TNBC) is defined by the
absence of estrogen receptors, progesterone receptors and
HER-2 amplification and represents an aggressive breast
cancer subtype. Despite significant advancements in the
treatment of other breast cancer subtypes, there is still no
licensed targeted therapy available for the treatment of
TNBC, and therefore little improvement in survival has
been observed for this patient population over the last
years [1, 2]. This highlights the need for better understand-
ing of TNBC and identification of mechanisms involved in
disease progression and treatment response.
It is now well recognized that breast cancer progression
can be influenced by a pro-tumorigenic microenvironment
surrounding the malignant epithelial cells. This environ-
ment consists of a heterogeneous mixture of stromal cells,
including a diversity of cancer associated fibroblasts
(CAFs), a biological active network comprising the extra-
cellular matrix (ECM), in addition to the interstitial fluid
and its solutes [3, 4]. New knowledge about the compo-
nents of the microenvironment and how they interact with
tumor cells can hopefully identify new biomarkers or
potential targets in TNBC.
The aberrant stroma affects the physiological forces
within the tumor. Indeed, the hydrostatic pressure in the
tumor interstitium, known as interstitial fluid pressure
(PIF), is considerably increased in the majority of solid
tumors [5], including human breast cancer [6, 7], and
this poses a major physiological barrier to transport of
soluble factors within the tumor [8].
Increased PIF has been shown to predict poor prognosis
in some solid tumors [9, 10], and can also hinder effective
delivery of drugs into the tumor [11–13]. Finding ways to
lower tumor PIF may therefore increase efficiency of
cancer therapy.
Fibroblasts can actively modify PIF and transcapillary
fluid exchange (reviewed in [8, 14, 15]) and the molecular
mechanisms are outlined by collagen contraction assays
[16, 17] and heterospheroids [18–20], as well as parallel in
vivo experiments [21–23]. Dysfunctional blood and lymph
vessels will lead to fluid accumulation in the tumor inter-
stitium, and swelling of hyaluronan and proteoglycans
would in normal conditions hinder an increase in PIF [8,
24]. Tension exerted by fibroblasts and collagen network
can probably counteract this swelling, resulting in a per-
sistent increased PIF [14]. However, although
fibroblast-mediated contraction has previous been shown
to be dependent on β1-integrins [21], fibroblast-mediated
PIF influence is still not fully understood.
Integrin α11β1 is a collagen binding integrin expressed
during differentiation of myofibroblasts [25–27] and is in-
volved in collagen organization [17, 28] and tumor stiffness
[28]. As a collagen organizer and a link between contractile
fibroblasts and the complex collagen network, integrin
α11β1 could be a regulator of tumor PIF. Although a few
studies indicate that it has a physiological role in the regu-
lation of PIF in dermis [29, 30], its influence on PIF in tu-
mors remains to be demonstrated. A better understanding
of the mechanisms that regulate pressure homeostasis
within a tumor, can probably lead to a new insight into
breast carcinogenesis, and we therefore investigated the ef-
fect of stromal integrin α11-deficiency on pressure homeo-
stasis, ECM organization and tumor growth using two
human TNBC xenograft models.
Methods
Cell lines
MDA-MB-231 (ATCC® HTB-26™) was provided by Profes-
sor James Lorens (University of Bergen, Bergen, Norway),
and MDA-MB-468 (ATCC® HTB-132™) was obtained from
the American Type Culture Collection (Manassas, VA.,
USA). The MDA-MB-231 cells were fingerprinted before
use and matched with the cell line MDA-MB-231 (ATCC®
HTB-26™) in the ATCC database. MDA-MB-231 was used
at passage number five to nine, while the MDA-MB-468
cells were used at passage number two to five. These TNBC
cell lines have high tumor take in SCID mice and slowly
forming tumors, which may be more stromal dependent
than more rapidly growing xenografts. Wild type (WT) and
integrin α11-deficient (α11-KO) mouse embryonic
fibroblasts (MEFs) were obtained from mouse embryos of
embryonic day 14.5 as described previously [31]. In order
to obtain immortalized MEFs, primary MEF cultures were
infected with recombinant retrovirus-transducing simian
virus 40 (SV40) [32]. All cell lines were grown in Nutrient
Mixture F-12 Ham (Sigma-Aldrich, Steinheim, Germany)
supplemented with 10% Foetal Bovine Serum, 100 units/ml
penicillin, 100 μg/ml streptomycin, and 1–2% L-glutamine
(all from Sigma-Aldrich). The cells were grown as single
monolayers in a humidified incubator at 37 °C in 5% CO2
and in all experiments used at log phase. All cell lines
tested negative for mycoplasma contamination.
Xenograft models
The integrin α11-deficient heterozygous SCID mouse
strain was generated as previously described [28]. PCR-
genotyping was performed on DNA extracted from ear
biopsies [32]. The animals were kept in individually venti-
lated cages, cared for regularly and efforts were made to
age- and weight match the animals. All animal experiments
were approved by the Norwegian Food Safety Authority
(Permit Number 20168751) which is the competent body
responsible for authorizing research projects in animals in
Norway. This is in accordance with the EU directive 2010/
63 article 36.
A total of 5 × 105 MDA-MB-231 or 1.5 × 105 MDA-
MB-468 tumor cells in 0.15 ml PBS were injected into
the fourth mammary fat pad (orthotopic), and for the
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MDA-MB-231 also subcutaneously on the mouse flank
(ectopic). Tumor size was measured using a caliper. The
tumor volume was calculated using the formula; tumor
volume (mm3) = (π/6) × a2 × b, where a represents the
shortest diameter and b represents the longest diameter
of the tumor. All animals were anesthetized using Iso-
fluran (Isoba®vet. 100%, Schering-Plough A/S, Farum,
Denmark) and eventually sacrificed by cervical disloca-
tion under deep anesthesia. For investigation of the pri-
mary tumor, all the MDA-MB-231 injected mice were
sacrificed day 57 post injection. For the MDA-MB-468
injected mice, some of the tumors showed tendency to
ulcerate the skin, and these mice were sacrificed imme-
diately. To make the groups comparable, one mouse
from the opposite group and with similar tumor load
was sacrificed on the same day.
To evaluate metastatic spread to the lungs, they were
processed and fixed as previously described [33] (n= 5 WT
and 5 α11-KO and n= 5 WT and 4 α11-KO for the MDA-
MB-231 and MDA-MB-468 injected mice, respectively).
All measurements and analysis in this study were per-
formed blinded to genotype.
Measurement of interstitial fluid pressure
The wick-in-needle technique was used to measure the
tumor PIF [34]. Briefly, a standard 23-gauge needle with a
side hole filled with nylon floss and saline was connected
to a PE-50 catheter, a pressure transducer and a computer
for pressure registrations, using the software Powerlab
chart (version 5, PowerLab/ssp. AD instruments, Dunedin,
New Zealand). The needle was inserted into the central
part of the tumor after calibration. After a period of stable
pressure measurements, the fluid communication was
tested by clamping the catheter which shall cause a transi-
ent rise and then return to pressure prior to clamping.
Measurements were accepted if the pre- to post-clamping
value was within ±1mmHg.
PIF in heterospheroids was measured with the micro-
puncture technique described previously [18]. Briefly, the
spheroids were collected and transferred to 10-cm
Lysine-coated cell culture dishes (Nunc, Thermo Fisher,
Waltham, MA., USA) and left to attach for 2 h at 37 °C. PIF
was measured using sharpened glass capillaries (tip diam-
eter 3–5 μm) connected to a servo-controlled counter
pressure system. The glass capillaries were filled with
hypertonic saline (0.5M) colored with Evans blue dye and
inserted into the central parts of the spheroid with the help
of a stereomicroscope (Wild M5, Heerbrugg, Switzerland).
PIF in the cell culture medium directly outside the spheroid
was defined as the zero reference pressure.
Electron microscopy of collagen fibrils in the tumor
Tumor samples were taken from the tumor periphery
and were fixed and processed as previously described
[33]. A JEM-1230 Transmission Electron Microscope
(TEM) (Jeol, Tokyo, Japan) was used to measure the
diameter and organization of the collagen fibrils, and
images from four to six different areas of the tissue were
analyzed. Pictures were captured at × 100,000 magnifica-
tion and analyzed using Image J 1.46 (National Institute
of Health, Bethesda, MD., USA) to measure the fibril
diameter. To investigate the organization of the collagen
fibrils, pictures were captured at × 30,000 magnification
and scored from one to four considering collagen fibril
organization and alignment within the collagen fibers.
A JSM-7400F Scanning Electron microscope (Jeol) was
used to study the tumor collagen fibril scaffold architec-
ture. Five images from different areas of the tumor were
captured from each tumor at × 10,000 magnification.
Immunostaining and Picrosirius-red staining
Histological analysis was performed on both paraffin
embedded sections and cryosections. For paraffin
embedded sections, 5 μm thick sections were deparaffi-
nizated and rehydrated, followed by heat induced
antigen retrieval at pH 6 (#S1699, Dako, Agilent, Santa
Clara, CA., USA) for Ki67 (100 °C, 20 min) and αSMA
(100 °C, 25 min), pH 9 (#2367, Dako) for Coll III (100 °C,
25 min) or pH 10 (#T6455, Sigma Aldrich) for PDGFRβ
(110 °C, 5 min). After antigen retrieval, the sections were
incubated with peroxidase block (#K006, Dako) and then
primary antibody. Envision+ System-HRP (#K4006 or
#K4010, Dako) was used as secondary antibody, in
addition to rabbit anti-goat for collagen III (1:1000,
#6164–01, Southern Biotech, Birmingham, AL., USA),
and DAB was used as chromogen, except for αSMA
staining, where a FITC-conjugated antibody was used.
Analysis of immunohistochemistry was performed using
Leica DN 2000 Led (Leica Microsystems, Wetzlar,
Germany). The following primary antibodies were used
on paraffin sections: rabbit anti-mouse PDGFRβ mAb
(1:100, #3169, Cell Signaling Technology, Danvers, MA.,
USA), goat anti-mouse Type III Collagen pAb (1:100,
#1330–08, Southern Biotech), anti-mouse αSMA mAb
(F3777, dilution 1:200, Sigma Aldrich) and mouse
anti-human Ki67 mAb (1:100, #M7240, Dako).
Cryosections with a thickness of 6 μm were fixed in
ice-cold methanol (− 20 °C, 8min) and rehydrated with PBS,
followed by blocking with 10% goat serum. Afterwards, the
following primary antibodies were supplied: rabbit anti-
mouse integrin α11 pAb (1:200, custom-made, Innovagen
AB, Lund, Sweden, [31]), mouse anti-human cytokerain
AE1/AE3 mAb (1:200, #M3515, Dako) and mouse anti
αSMA mAb (1:200, #A5228, Sigma Aldrich). Goat anti-
rabbit Alexa 594 (1:400, #111–585-144, Jackson ImmunoRe-
search, Ink., West Grove, PA., USA) and goat anti-mouse
Alexa 488 (1:400, #315–545-045, Jackson ImmunoResearch)
were used as secondary antibodies. Mounting was done with
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ProLong Gold Antifade Mountant with DAPI (#P36934,
ThermoFisher). The staining results were evaluated under
an Axioscope fluorescence microscope and micrographs
were acquired using a digital AxioCam MRm camera (Zeiss,
Oberkochen, Germany).
Picrosirius-red stain (Polysciences inc, Warrington,
FL., USA) was used for a semi-quantitative measurement
of collagen type I and III as previously described [33].
Evaluation of the staining
For Picrosirius-red, collagen III, PDGFRβ and αSMA, a
total of four to six pictures were captured from each
tumor with × 100 magnification. Images were taken in the
tumor periphery in order to avoid the necrotic central
area. The software Image J 1.46 (National Institute of
Health, Bethesda, MD., USA) was used to identify the
amount of positive pixels.
For Ki67, the tumors were examined using light micros-
copy with an eye-piece grid at × 630 magnification. A total
of 500 tumor cells from the tumor periphery were evalu-
ated, and distinct nuclear staining regardless of intensity
was registered as positive. Areas with necrosis, bleeding or
inflammation were avoided.
Microdialysis
Microdialysis was performed as previously described [35]
on the MDA-MB-231 mammary fat pad tumors. Briefly,
after anesthesia with Ketalar (Pfizer Inc., NY., USA) and
Dormitor (Orin Pharma AS, Espoo, Finland), one microdi-
alysis probe was placed in the MDA-MB-231 mammary
fat pad tumor (CMA12 Elite Microdialysis probe, ref.nr
8,010,434) and one in the jugular vein (CMA12 Elite
Metal free, ref.nr 80,111,204). The probes were connected
to a PE-50 catheter, perfused by a pump (CMA100 Micro-
injection pump, ref.nr 8,210,040) at a rate of 1 μl/min and
left to stabilize for 30min. After intravenous injection of
0.15ml 0.65MBq 3H-5FU (Nycomed Amersham, Buck-
inghamshire, UK), dialysate was sampled and pooled every
10min for a total of 90min. Scintillation counting
solution (Optiphase Hisafe 3, PerkinElmer, Inc., Waltham,
MA., USA) was added, and the radioactivity measured
using a liquid scintillation analyzer (Tri-Carb 2900TR,
PerkinElmer, Inc.). The probes and pump were delivered
by CMA Microdialysis AB, Kista, Sweden.
The area under the curve (AUC) for the plasma and
tumor was calculated with Graph Pad Prism 7 (GraphPad
Software Inc., La Jolla, CA., USA) as the total radioactivity
collected, i.e. as the product of radioactivity (counts per
minute) and time. Finally, transport of 3H-5FU was
expressed as AUC tumor divided by AUC plasma.
After each experiment, the probes were tested in sa-
line with a known amount of 3H-5FU, and experiments
with probes that differed more than 15% in permeabil-
ity were excluded.
Heterospheroids
Heterospheroids containing a mixture of SV40-immortal-
ized MEFs and MDA-MB-231 cells were prepared using
the hanging drop method as described previously [19].
Briefly, sub-confluent cells were trypsinized and sus-
pended in culture medium to a concentration of 1 × 106/
ml. The MEFs (WT or integrin α11-KO MEFs) and
MDA-MB-231 cell suspensions were then mixed at a ratio
of 4:1 to make WT MEFs + MDA-MB-231 and α11-KO
MEFs + MDA-MB-231 spheroids. Approximately 40
drops (25 μl/ drop, 2.5 × 104 cells/drop) were dispensed
onto a lid of a cell culture dish. The lid was then inverted
and placed over a cell culture dish containing medium for
humidity, and cultured in a humidified incubator at 37 °C
in 5% CO2 for 5 days.
Statistical analysis
Sigmaplot 13.0 (Systat Software Inc., Chicago, IL., USA)
and Graph Pad Prism 7 (GraphPad Software) were used
for statistical analysis. Either the unpaired two-tailed
t-test or the Mann- Whitney U test, was used to analyze
statistical differences between the two groups. Results
were accepted as statistically different when p < 0.05. Data
are given as mean ± SD, and number of measurements (n)
refers to number of tumors or heterospheroids unless
otherwise specified.
Results
Effect of stromal integrin α11β1 on breast tumor growth
MDA-MB-231 and MDA-MB-468 tumor cells were
injected into WT and α11-KO mice. As expected, we
found that integrin α11 was expressed in the tumor stroma
in WT mice, but not in α11-KO mice (Fig. 1d). Further-
more, the immunofluorescent staining of integrin α11 (Fig.
1d) did not show differences in the amount of integrin α11
expression between the MDA-MB-231 orthotropic and
subcutaneous model (n = 3–5). The tumor volumes in
MDA-MB-231 mammary fat pad tumors were significantly
reduced (p < 0.01) in α11-KO mice compared to tumors
grown in WT mice during their 57 days growth period
(Fig. 1a). A clear tendency towards reduced MDA-MB-468
mammary fat pad tumor growth was also seen, but this did
not reach statistical significance (p = 0.059) (Fig. 1b). Of
note, there was no difference in MDA-MB-231 tumor
growth when the cells were injected subcutaneously on the
back (Fig. 1c).
In the MDA-MB-231 mammary fat pad tumors, there
was a slight, but statistically significant difference in the
number of proliferating tumor cells, indicated by posi-
tive Ki67 staining (Fig. 2a and d). However, in the two
other tumor models, there were no significant differ-
ences in number of proliferating tumor cells (Fig. 2b-d).
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Integrin α11-deficiency reduces tumor interstitial fluid
pressure
The tumor PIF was measured by the wick-in-needle
method. PIF was significantly reduced in both MDA-
MB-231 and MDA-MB-468 mammary fat pad tumors
grown in α11-KO mice compared to WT (Fig. 3a-b). No
difference in PIF was seen in the MDA-MB-231 subcuta-
neous tumors (Fig. 3c).
Integrin α11-deficiency perturbs collagen structure
Picrosirius-red and collagen III staining did not demon-
strate differences in the amount of collagen in either of the
tumor models (Fig. 4a-c and Additional file 1: Figure S1).
Collagen fibril organization and structure in the xeno-
graft tumors were investigated using TEM. As seen in
Fig. 5a-b and d, integrin α11-deficiency lead to more disor-
ganized collagen fibril architecture with fewer aligned col-
lagen fibrils in both the MDA-MB-231 and MDA-MB-468
mammary fat pad tumor models. In these tumors, there
was also a shift towards thinner collagen fibrils in α11-KO
compared to WT mice (Fig. 6a-b and d). No difference was
seen in either collagen fibril alignment or collagen fibril
diameter in the MDA-MB-231 subcutaneous tumors when
comparing α11-KO mice with WT (Figs. 5c and 6c). In
addition, SEM did not demonstrate visual differences in
the collagen fibril structure between tumors grown in
α11-KO mice versus WT (Fig. 7).
Immunostaining of αSMA and PDGFRβ, common
markers of activated fibroblasts and pericytes, was used to
quantify the relative amount of activated fibroblasts in the
tumor stroma. Although integrin α11 partially co-localized
with αSMA in xenograft tumors in WT mice (Fig. 8c), no
significant differences in the amount of PDGFRβ or αSMA
expression (Fig. 8a-b and Additional file 1: Figure S1) in
tumors in α11-KO compared to WT mice were found.
Integrin α11β1 does not affect uptake of 3H-5FU
The reduced tumor PIF found in MDA-MB-231 mam-
mary fat pad tumors in α11-KO mice was not associated
with increased uptake of 3H-5FU measured by microdi-
alysis (Fig. 9).
Pressure homeostasis and integrin α11β1 in
heterospheroids
Since the in vivo results demonstrate that stromal integrin
α11β1 has a role in maintaining pressure homeostasis in
triple-negative breast xenograft tumors, we also investi-
gated the isolated effect of integrin α11-positive fibroblasts
on tumor PIF in a simplified system. Spheroids composed
Fig. 1 Tumor growth. The growth of MDA-MB-231 and MDA-MB-468 xenograft tumors (a-c) in WT and α11-KO mice. A total of 5 × 105 MDA-MB-
231 and 1.5 × 106 MDA-MB-468 cells were injected into the mammary fat pad, and for MDA-MB-231, also subcutaneously (s.c.) on the back. All
MDA-MB-231 injected mice were sacrificed at day 57 post injection. The MDA-MB-468 injected mice were sacrificed at different time points
starting with n = 20 WT and n = 16 α11-KO. Mean ± SEM. ** p < 0.01. Immunofluorescence staining of integrin α11 (red), cytokeratin AE1/AE3
(green) and DAPI (blue) in MDA-MB-231 and MDA-MB-468 xenograft tumors (d) in WT and α11-KO mice. Scale bars indicate 50 μm
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of fibroblasts lacking integrin α11 grown together
with MDA-MB-231 cells had significantly lower PIF
compared to spheroids with MDA-MB-231 cells and
WT fibroblasts (Fig. 10a-b). These data indicate that
the difference in PIF is, at least in part, due to integ-
rin α11-positive fibroblasts.
Tumor metastases
No lung metastases were seen when investigating
coronal HE stained sections from lungs at end stage.
Discussion
Integrins are essential adhesion receptors necessary for
intercellular communication, attachment of cells to the
ECM and modulation of the tumor microenvironment
[36–39]. In this study, we have demonstrated that stromal
integrin α11-deficiency markedly decreased PIF in vivo
using two orthotopic human triple-negative breast cancer
cell lines. A perturbed collagen structure was seen, with
fewer aligned and thinner collagen fibrils. Furthermore,
integrin α11-deficiency impeded orthotopic breast tumor
growth in the MDA-MB-231 model, and the same trend
Fig. 2 Tumor cell proliferation. The fraction of Ki67-positive tumor cells in MDA-MB-231 and MDA-MB-468 xenograft tumors (a-c). Reduced
percentage of Ki67-positive tumor cells was only seen in MDA-MB-231 mammary fat pad tumors in α11-KO mice compared to WT (n = 7 for
MDA-MB-231 and MDA-MB-468 mammary fat pad tumors, and n = 4 WT and n = 5 α11-KO for MDA-MB-231 subcutaneous tumors). Mean ± SD. *
p < 0.05. Representative images of Ki67 staining of sections from all xenograft tumors in WT and α11-KO mice (d). Scale bars indicate 100 μm
Fig. 3 Tumor interstitial fluid pressure. The individual interstitial fluid pressures (PIF) in MDA-MB-231 and MDA-MB-468 xenograft tumors (a-c) in
WT and α11-KO mice. The horizontal lines indicate the mean values. Reduced tumor PIF was seen in MDA-MB-231 and MDA-MB-468 mammary
fat pad tumors in α11-KO mice compared to WT, but no difference was seen in the MDA-MB-231 subcutaneous tumors. * p < 0.05
Smeland et al. BMC Cancer          (2019) 19:234 Page 6 of 13
was also found in the MDA-MB-468 orthotopic model. By
investigating the isolated effect of integrin α11-positive
fibroblasts on MDA-MB-231 tumor cells in vitro, we pro-
vide here evidence that PIF regulation is, at least partly,
mediated by integrin α11-positive fibroblasts.
Integrin α11β1 has arisen as a possible marker of a
pro-tumorigenic subset of CAFs in the tumor micro-
environment [40, 41]. It has been found to be overex-
pressed in the stroma of lung cancer and head and neck
cancer [40, 42]. Further, it stimulates lung cancer cell
Fig. 4 Collagen amount. The total fraction of Picrosirius-red and collagen III positive staining quantified in MDA-MB-231 (a) and MDA-MB-468
mammary fat pad tumors (b) in WT and α11-KO mice showed no differences (n = 6 in both models). Mean ± SD. Representative images of
Picrosirius-red staining of sections from MDA-MB-231 and MDA-MB-468 mammary fat pad tumors in WT and α11-KO mice (c). Scale bars
indicate 100 μm
Fig. 5 Collagen fibril organization. Transmission electron microscopy pictures from the xenograft tumors were scored from 1 to 4 according to
collagen organization. The average collagen organization score per tumor in MDA-MB-231 (a) and MDA-MB-468 mammary fat pad tumors (b)
were lower in α11-KO mice compared to WT (n = 8 WT and n = 7 α11-KO mice in both models). No difference was found in the MDA-MB-231
subcutaneous tumors (c) (n = 5). Mean ± SD. * p < 0.05, ** p < 0.01. Examples of the different scoring values from MDA-MB-468 tumors are shown
in (d) (1- highly disorganized, 2-moderately disorganized, 3-moderately organized and 4-highly organized). Scale bars indicate 0.5 μm
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growth in vitro [20], and lung and prostate cancer
growth in vivo [28, 33]. However, its role in tumor
growth and progression is still not clear, especially in
breast tumors where we recently reported that it did not
affect the growth of the murine TNBC cell line 4 T1 in
vivo [33].
In the present study, we found that stromal integrin
α11-deficiency led to reduced tumor PIF in both ortho-
topic xenograft models. This demonstrates for the first
time that integrin α11β1 has a role in maintaining an
elevated PIF in solid tumors. A dense ECM, contractile
fibroblasts, leaky blood vessels and dysfunctional
lymphatic drainage are possible causes of increased PIF
in tumors [8]. PIF can be actively modulated through
interactions between contractile fibroblasts and ECM
molecules [8, 23], where fibroblasts have been proposed
to normally exert a tension on the collagen network
through collagen-binding integrins [14]. Furthermore,
integrin α11β1 contracts collagen matrices experimen-
tally [17], and we therefore suggest that integrin
α11β1-mediated PIF modifications can involve a
contraction of the interstitial space mediated by direct
or indirect binding of integrin α11-positive fibroblasts
to collagen.
The involvement of integrin α11-positive fibroblasts in
tumor PIF homeostasis is supported by our study of het-
erospheroids, where we observed a similar PIF reduction
in spheroids composed of MDA-MB-231 cells and integ-
rin α11-deficient fibroblasts. This simplified system
allows us to investigate how fibroblasts grown together
with tumor cells can influence PIF [18–20]. In line with
our results, a similar integrin α11β1 function in pressure
regulation has previously been shown in fibroblasts/lung
cancer heterospheroids [20]. However, although these
avascular spheroid studies indicate that the pressure
regulatory abilities of integrin α11β1 is, at least in part,
mediated by integrin α11-positive fibroblasts, the mech-
anisms behind integrin α11-mediated effect on PIF in
heterospheroids are not investigated in detail in this
study. In addition, we cannot exclude additional factors
in the more complex in vivo system, such as influence of
the tumor vasculature, which has been shown to have an
important impact on tumor PIF [13, 43–45].
Furthermore, integrin α11-deficiency led to less organized
and thinner collagen fibrils in the orthotopic models, which
could be a contributing factor to reduced tumor PIF. Al-
though it has been shown that the collagen-binding proteo-
glycan fibromodulin promotes the formation of a dense
Fig. 6 Collagen fibril diameter. Transmission electron microscopy (TEM) was used to analyze collagen fibrils. Collagen fibril diameter distribution
and average fibril diameter per tumor in MDA-MB-231 (n = 7) (a) and MDA-MB-468 mammary fat pad tumors (n = 7) (b) showed a shift towards
thinner fibrils in α11-KO mice compared to WT. No difference was seen in MDA-MB-231 subcutaneous tumors (c) (n = 5). Mean ± SD. * p < 0.05.
Representative TEM images of collagen fibrils in MDA-MB-231 and MDA-MB-468 mammary fat pad tumors in both genotypes (d). Scale bars
indicate 0.2 μm
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stroma and increased tumor PIF [46], it is nevertheless diffi-
cult to predict how different components in the extracellu-
lar matrix affect the hydraulic conductivity of tissues and
thereby fluid flow and PIF [47].
Although the present study is the first to identify in-
tegrin α11β1 as participating in regulation of pressure in
solid tumors, it is already known to maintain a homeo-
static PIF in dermis [29, 30]. Furthermore, we have pre-
viously demonstrated the function of β1-integrins in the
regulation of dermal PIF by inhibiting β1-integrins [21].
Numerous studies have highlighted the role of CAFs
in tumor progression, invasion and metastasis, either
Fig. 8 αSMA and PDGFRβ. The total fraction of αSMA and PDGFRβ positive staining quantified in MDA-MB-231 (a) and MDA-MB-468 mammary
fat pad tumors (b) in WT and α11-KO mice showed no differences (n = 6 in both models). Mean ± SD. Immunofluorescence staining of integrin
α11 (red), αSMA (green) and DAPI (blue) in MDA-MB-231 and MDA-MB-468 mammary fat pad tumors in WT and α11-KO mice (c). Scale bars
indicate 50 μm
Fig. 7 Collagen fibril architecture. Representative scanning electron images of collagen fibrils in MDA-MB-231 and MDA-MB-468 mammary fat
pad tumors in WT and α11-KO mice (n = 5 WT and n = 4 α11-KO in both models). Scale bar indicates 1 μm
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directly by stimulation of tumor cells via production of
pro-tumorigenic growth factors or indirectly by for ex-
ample remodeling the ECM (reviewed in [48]). Here we
show that integrin α11β1, known to be expressed during
myofibroblast differentiation [25, 26], seems to facilitate
breast tumor growth in vivo.
In previous studies, the pro-tumorigenic abilities of in-
tegrin α11β1 have been associated with increased matrix
stiffness, collagen reorganization and increased levels of
IGF-2 [28, 40]. In the present study, changes in pressure
homeostasis and collagen organization could both influ-
ence tumor growth and invasion. Of interest, increased
tumor PIF has been linked to tumor aggressiveness in
some human cancers [9, 49], and is an independent poor
prognostic factor in cervical cancer [10, 50].
There have been reports suggesting that increased tumor
PIF can both facilitate and inhibit tumor progression. First,
major pressure gradients due to increased tumor PIF can
enhance interstitial fluid flow at and lymph drainage from
the tumor margins, which probably increase the risk of
cancer cells leaving the tumor. Increased flow can also fa-
cilitate tumor progression indirectly by either mechano-
modulation of the tumor stroma or by changing the host
immune response and thereby promote immunological
tolerance (reviewed in [51, 52]). Further, in vitro elevation
of tumor PIF increased proliferation of human osteosar-
coma [53] and oral squamous cell carcinoma cells [54].
Similarly, in vivo lowering of tumor PIF, and thereby reduc-
tion of mechanical stretch for 24 h, reduced tumor cell
proliferation in vulva and lung xenograft tumors [55]. How-
ever, contrary to these findings, increased tumor PIF may
also limit uptake of nutrition and growth factors into the
tumor and thereby inhibit tumor cell progression [8]. In the
context of breast cancer, MDA-MB-231 cells have actually
been shown to invade towards regions of higher pressure in
vitro [56, 57], indicating that the elevated tumor PIF may in
fact restrain breast tumor invasion. In summary, these find-
ings demonstrate that maintenance of a high tumor PIF
may be a contributing factor to integrin α11β1’s pro-
tumorigenic effects, but at the same time, it can have
opposite effects during tumorigenesis, pinpointing the need
for further preclinical investigation.
Although increased tumor PIF can be a major barrier
in cancer treatment, lowering of tumor PIF by integrin
α11-deficiency did not increase the uptake of the low
molecular weight drug 3H-5FU into MDA-MB-231
tumor interstitium. Low molecular weight compounds
are transported by both diffusion and bulk flow/convec-
tion, and we have previously shown that reducing PIF
can increase the uptake of the small molecular weight
drugs 3H-5FU [11, 58] and 51Cr-EDTA [12, 59] into the
tumor interstitium. However, in parallel with the results
in the present study, it is evident that lowering of PIF
will not always increase the uptake of low molecular
Fig. 10 Heterospheroids. The individual interstitial fluid pressures (PIF) in heterospheroids containing a mixture of mouse embryonic fibroblasts
(MEFs) and MDA-MB-231 breast tumor cells (4:1) (a). α11-KO MEFs + MDA-MB-231 spheroids showed a significant reduction in PIF compared to
WT MEFs + MDA-MB-231 spheroids. *** p < 0.001. Transmission electron microscopy images show collagen fibrils in both heterospheroid
types (b)
Fig. 9 Microdialysis. Dialysate was sampled for 90 min after i.v.
injection of 3H-5FU, and the ratio between 3H-5FU level in plasma
and in MDA-MB-231 mammary fat pad tumor was calculated as Area
Under Curve (AUC). There was no significant difference in uptake
when WT and α11-KO mice were compared (n = 5). Mean ± SD
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weight drugs [35, 60]. Similarily, Flessner et al. showed
that decapsulation of ovarian xenografts markedly
decreased PIF to zero, but did not increase penetration
of the high molecular weight drug trastuzumab into the
tumor [61]. In summary, probably other features of the
tumor microenvironment can also contribute to the
failure of transport within solid tumors [5, 61].
Our data show that integrin α11-deficiency leads to
thinner and less organized collagen fibrils in the orthoto-
pic tumor stroma. Changes in collagen composition and
organization are already known to influence tumorigenesis
and can predict breast cancer behavior [3]. For example,
progressive deposition of collagen [62] and increased col-
lagen fiber linearization [63, 64] are associated with breast
cancer aggressiveness.
While integrin α11-deficiency influenced tumor growth
and reduced PIF with concomitantly more disorganized
collagen fibrils in the orthotopic tumors, no effect was
seen in the MDA-MB-231 ectopic tumors. Interestingly,
there was similar amount of integrin α11β1 expression in
both the MDA-MB-231 models. In a previous study, we
also observed that while integrin α11-deficiency reduced
RM11 tumor growth, but did not affect 4 T1 tumor
growth, the integrin α11β1 expression was not higher in
RM11 than in 4 T1 tumors [33]. Thus, differences in
integrin α11β1-expression cannot explain the contrasting
effect seen in these in vivo models.
The different effects seen between the MDA-MB-231
orthotopic and ectopic tumors show that tumor location
significantly influences the effect of integrin α11β1 in
vivo. The tumor microenvironment displays a significant
heterogeneity [65], and the subcutaneous location prob-
ably does not always give rise to a representative
tissue-specific stromal infiltration [66–68]. Supporting
the fact that the organ-specific fibroblasts influence
breast tumor growth differently, co-injection of breast
fibroblast with breast tumor cells increased tumor
growth, whereas no enhancement was seen with the
co-injection of skin fibroblasts [69]. The significance of
the local microenvironment illustrates the complexity of
in vivo studies, and may explain some of the discrepancies
seen with different mouse models. This underlines the im-
portance of choosing the appropriate preclinical model,
particularly when investigating the tumor microenviron-
ment. If possible, orthotopic models should be preferred
rather than ectopic ones.
Conclusion
Our findings indicate an important role for integrin
α11β1 in interstitial fluid pressure regulation in the
breast tumor microenvironment. Further, since integrin
α11β1 seems to impede breast cancer growth, it may be
an interesting candidate for stromal targeted therapy.
Additional file
Additional file 1: Figure S1. Collagen and activated fibroblasts in MDA-
MB-231 subcutaneous tumors. The total fraction of Picrosirius-red, αSMA
and PDGFRβ positive staining demonstrated no differences between
MDA-MB-231 subcutaneous tumors in WT and α11-KO mice (n = 3 WT
and n = 4 α11-KO). Mean ± SD. (TIF 242 kb)
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Fig S1. Collagen and activated fibroblasts in MDA-MB-231 subcutaneous tumors. The total 
fraction of Picrosirius-red, αSMA and PDGFRβ positive staining demonstrated no differences 
between MDA-MB-231 subcutaneous tumors in WT and α11-KO mice (n=3 WT and n=4 α11-
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Abstract
Cancer-associated fibroblasts are essential modifiers of the tumor microenvironment. The collagen-binding integrin
α11β1 has been proposed to be upregulated in a pro-tumorigenic subtype of cancer-associated fibroblasts. Here,
we analyzed the expression and clinical relevance of integrin α11β1 in a large breast cancer series using a novel
antibody against the human integrin α11 chain. Several novel monoclonal antibodies against the integrin α11 sub-
unit were tested for use on formalin-fixed paraffin-embedded tissues, and Ab 210F4B6A4 was eventually selected
to investigate the immunohistochemical expression in 392 breast cancers using whole sections. mRNA data from
METABRIC and co-expression patterns of integrin α11 in relation to αSMA and cytokeratin-14 were also investi-
gated. Integrin α11 was expressed to varying degrees in spindle-shaped cells in the stroma of 99% of invasive
breast carcinomas. Integrin α11 co-localized with αSMA in stromal cells, and with αSMA and cytokeratin-14 in
breast myoepithelium. High stromal integrin α11 expression (66% of cases) was associated with aggressive breast
cancer features such as high histologic grade, increased tumor cell proliferation, ER negativity, HER2 positivity, and
triple-negative phenotype, but was not associated with breast cancer specific survival at protein or mRNA levels. In
conclusion, high stromal integrin α11 expression was associated with aggressive breast cancer phenotypes.
Keywords: integrin α11β1; monoclonal antibody; breast cancer; cancer associated fibroblasts; myoepithelial cells; clinico-pathologic
features
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Introduction
Breast cancer is a heterogeneous disease developed
from genetically altered mammary epithelial cells, and
there is a complex interplay between tumor cells and
the surrounding tumor microenvironment (TME). The
TME consists of various stromal cells, the extracellular
matrix (ECM) scaffold, and the interstitial fluid, and
both cellular and noncellular components have been
shown to play an active role in tumor development,
progression and metastasis [1]. Features of the TME
contribute to clinically relevant variations in breast
cancer phenotypes and have also been shown to pre-
dict patient outcome [2,3].
Integrins are transmembrane cell-surface receptors
crucial for bidirectional communication between cells
and the surrounding ECM [4]. The collagen receptor
integrin α11β1 has emerged as a potentially important
marker which is upregulated in fibroblasts during their
differentiation into an activated phenotype [5–7]. Acti-
vated fibroblasts in the TME, termed cancer-associated
fibroblasts (CAFs), constitute an abundant stromal cell
type, especially in tumors with high stromal content
such as pancreatic and breast carcinomas [1,8].
© 2019 The Authors. The Journal of Pathology: Clinical Research published by The Pathological
Society of Great Britain and Ireland and John Wiley & Sons Ltd.
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Accumulating data suggest the existence of diverse
CAF subtypes, which differ in their biological func-
tions, source of origin and expression of various
markers [9–14]. Different fibroblasts may vary in their
proliferative, secretory and contractile abilities and,
most importantly, their influence on tumor growth and
progression [9–14].
Integrin α11β1 contributes to fibroblast function in
wound healing, fibrosis and in different tumor models
(reviewed in Zeltz and Gullberg [5]), binds to fibrillar
collagen [15], and has been linked to collagen reorga-
nization [5,15] and tumor interstitial fluid pressure
[16,17]. In vivo, stromal integrin α11-deficiency
reduced the growth of triple-negative breast cancer
[16] and prostate cancer xenografts [18], and reduced
primary tumor growth [19,20] and metastasis [20] in
lung cancer xenografts models. Thus, integrin α11β1
could potentially represent a novel marker for a tumor-
supportive subtype of CAFs and thereby play an
important role in breast cancer progression.
The lack of reliable anti-human integrin α11 anti-
bodies has limited the investigation of integrin α11 in
retrospective studies using formalin-fixed and paraffin-
embedded (FFPE) tumor material. We here present for
the first time a study of integrin α11 expression in a
large human breast cancer cohort with long-term
follow-up, using a new in-house antibody specific for
the human integrin α11 chain, aiming to investigate
the expression of integrin α11 in human breast cancer,
associations with aggressive phenotypes, as well as
potential prognostic impact.
Materials and methods
Anti-human integrin α11 antibodies
Mouse monoclonal antibodies reactive to the extracel-
lular domain of the integrin α11 subunit were gener-
ated by NanoTools (Teningen, Germany) for CCBIO
(Centre of Cancer Biomarkers, University of Bergen,
Bergen, Norway) as described in [21] and conducted
in accordance with the German Animal Welfare Act
and approved by the local German Authorities
(RP Freiburg, AZ35/9185.82/I-13/03). In brief, mice
were immunized with soluble human integrin α11β1.
Primary hybridoma screening was performed as
described in [21]. In brief, selected hybridomas were
reactive to C2C12-α11 cells, but not to C2C12,
C2C12-α2 cells or A431 (expressing integrin β1 and a
variety of integrin α chains such as α2, α3, and α5,
but not integrin α11 [22]). Secondary hybridoma
screening was performed with flow cytometry and
western blotting as described elsewhere [23]. Anti-
integrin α11 antibodies were then tested on FFPE
tissue.
Mouse monoclonal antibodies reactive to the cyto-
plasmic domain of integrin α11 subunit were gener-
ated using the peptide H-CRREPGLDPTPKVLE-OH
by Oslo University Hospital (Oslo, Norway). The pep-
tide was custom-synthesized and conjugated to key-
hole limpet hemocyanin (KLH) (Mimotopes, Clayton,
Australia). BALB/c mice were immunized with the
peptide-KLH conjugate and hybridomas constructed
by fusion of splenocytes with the NS0 myeloma cell
line (approved by the Norwegian Food Safety Author-
ity with permit number 7903). Primary hybridoma
screening was performed using antibody capture
assays with biotinylated peptide (Biotin-SGSGRREP
GLDPTPKVLE-OH) presented on streptavidin-coated
96-well microplates (Wallac Oy, Turku, Finland).
Secondary screening was undertaken by western blot-
ting and immunostaining of integrin α11-positive and
-negative cell lines and also frozen sections of pan-
creatic ductal adenocarcinoma (PDAC). D120.4 was
then selected for use on FFPE tissue.
Monoclonal antibodies were purified from hybridoma
culture supernatants by protein-A chromatography.
Cell culture
The integrin α11- or α2- overexpressing C2C12 cell
lines, C2C12-α11, or C2C12-α2, were prepared as
described previously [15], while U2OS and HEK293
were purchased from the American Type Culture
Collection (ATCC, Manassas, VA, USA). All cells
were cultured in DMEM with Glutamax (Gibco,
Gaithersburg, MD, USA) supplemented with 10%
fetal bovine serum, 100 units/ml of penicillin and
0.1 mg/ml of streptomycin (all from GE Healthcare,
Chicago, IL, USA) under standard culture conditions
(5% CO2, 37 C).
Western blotting and RT-qPCR
The cells were cultured to subconfluence and washed
with PBS, lysed and collected in RIPA buffer
(150 mM NaCl, 50 mM Tris base, 0.1% sodium dode-
cyl sulfate, 12 mM deoxycholate, 1% Nonidet-P40, 1%
Triton X-100, pH 8) and supplemented with protease
inhibitors (Roche Diagnostics, Basel, Switzerland).
Protein concentration was determined by BCA assay
(Bio-Rad, Hercules, CA, USA) after centrifugation. Of
cleared lysates, 20 μg were analyzed by SDS-PAGE
and blotted onto PVDF membranes (Millipore, Bur-
lington, MA, USA). The antibodies used were as
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follows: mouse anti-human monoclonal integrin α11
antibody 210F4B6A4 (custom-made by NanoTools for
CCBIO) (2.9 μg/ml), mouse anti-human monoclonal
integrin α11 antibody D120.4 (custom-made by Oslo
University Hospital) (2.8 μg/ml), rabbit anti-human
polyclonal integrin α11 antibody [24] (1,9 μg/ml),
anti-β-actin (Sigma–Aldrich, Steinheim, Germany)
(1:5000), in addition to goat anti-rabbit and goat
anti-mouse HRP-conjugated antibodies (Santa Cruz
Biotechnology, Dallas, TX, USA) (1:5000). Chemilu-
minescence signals were developed using the ECL
Western-blotting systems kit (GE Healthcare) and
photographed using the ChemiDoc XRS device and
the Quantity One 1-D Analysis Software (Bio-Rad).
RT-qPCR was performed as previously described
[6]. In brief, total RNA was prepared from the cells
using RNeasy Mini Kit (Qiagen, Hilden, Germany),
and 1 μg RNA was used for reverse transcription to
cDNA using iScript Reverse Transcription Supermix
(Bio-Rad). qPCR mixtures were prepared with 20 ng
of reverse-transcribed cDNA as a template, along with
0.5 μM of each primer, in a 10 μl qPCR using iQ
SYBR Green Supermix (Bio-Rad). The qPCR was
performed in a LightCycler 480 Instrument II (Roche
Diagnostics). The reactions were prepared in triplicate
for individual cDNA sample along with the negative
controls where no cDNA was added for each primer
pair. The experiment was repeated three times. The
primers used were for target gene ITGA11 and two ref-
erences genes 18S rRNA and β-actin, and their
sequences are shown in Table 1.
FFPE cell pellets
The cell lines were collected at subconfluence, cen-
trifuged and washed with PBS. Plasma (Octaplas,
Haukeland University Hospital, Bergen, Norway) and
thrombin (Merck, Darmstadt, Germany) were added
sequentially, and the pellets were fixed in 4% formal-
dehyde for 24 h and transferred to ethanol/xylene prior
to embedding in paraffin wax.
Pancreatic ductal adenocarcinomas
Expression of the integrin α11 chain was investigated
in corresponding cryosections and FFPE sections from
five different PDACs from a research biobank
(Regional Ethical Committee approval 2013/1772) col-
lected at Haukeland University Hospital [25].
Breast cancer series
Integrin α11 expression was investigated in a
population-based cohort of 534 women diagnosed with
primary invasive breast carcinoma (aged 50–69 at
diagnosis) during 1996–2003 who resided in
Hordaland County in Norway, as described previously
[26]; treatment was given according to standard
national guidelines at the time. Patients with distant
metastatic disease at diagnosis were not included.
Also, 14 cases were not included because of insuffi-
cient tissue in remaining blocks, leaving 520 cases for
initial inclusion. Follow-up data were provided by the
Norwegian Cause of Death Registry. Median follow-
up time of survivors was 216 months (range
166–256), and last follow-up date was 30 June 2017.
The study was approved by the Regional Committee
for Medical and Health Sciences Research Ethics
(REK #2014/1984), and was performed in accordance
with the Declaration of Helsinki. In accordance with
national ethics guidelines and procedures for such ret-
rospective studies, all participants were contacted with
written information on the study and asked to respond
if they objected.
Immunohistochemistry
Cryosections of PDACs (4–5 μm) were fixed in ace-
tone, rehydrated with PBS, and endogenous peroxi-
dase activity was blocked with peroxidase block
(Dako, K4007, Agilent, Santa Clara, CA, USA). Anti-
integrin α11 210F4B6A4 (0.39 μg/ml) was incubated
in a humidity chamber overnight (4 C), followed by
HRP-labeled anti-mouse antibody (Dako, K4001)
(30 min), diaminobenzidine (DAB) (5 min) and hema-
toxylin (Dako, S2020) (3 min). A polyclonal antibody
[24] and the new monoclonal antibody 203E3, recently
demonstrated to be suitable for immunostaining of
cryosections [21], were used as controls.
Immunohistochemical staining of FFPE tumor tissue
was done on whole tissue sections (4–5 μm) mounted
on poly-lysine coated glasses. The sections were baked
Table 1. Primer sequences for qPCR
Gene symbol Forward primer Reverse primer Amplicon size (bp)
ITGA11 50-CACGACATCAGTGGCAATAAG 50-GACCCTTCCCAGGTTGAGTT 132
18S rRNA 50-GCAATTATTCCCCATGAACG 50-GGGACTTAATCAACGCAAGC 68
ACTB 50-GTGTGATGGTGGGAATGGGT 50-TCTGGGTCATCATTTCACGGTTGG 240
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at 56 C for 48 h followed by cooling to room temper-
ature (RT) (20 min), dewaxed with xylene/ethanol,
and antigen retrieval was performed in Target
Retrieval Solution pH 9 (Dako, K8010) (120 C,
10 min) in a pressure cooker (Decloaking Chamber
Plus, Biocare Medical, Pacheco, CA, USA). Staining
was performed using a Dako autostainer Plus (Dako)
with EnVision FLEX+ kit (Dako, K801021-2). Peroxi-
dase Block was applied for 8 min, followed by incuba-
tion with anti-integrin α11 210F4B6A4 (0.29 μg/ml)
(1 h RT), FLEX+ Mouse Linker (Dako, K8022)
(15 min), FLEX+ HRP (20 min), DAB (5 min) and
hematoxylin (3 min). Integrin α11-positive and
integrin α11-negative FFPE cell pellets in addition to
serial sections from one invasive breast carcinoma
were used as biological controls. An anti-human
IgG2b antibody was used as isotype control. Positive
and negative controls were included in each run.
Efforts were made to reduce the loss of tissue, such as
baking prior to the IHC protocol, and using freshly cut
sections and poly-lysine coated glasses.
For double and triple immunohistochemical staining,
deparaffinization/rehydration and antigen retrieval were
done as described above. Triple staining with antibodies
against integrin α11, αSMA and factor VIII (FVIII)
was done on 20 FFPE invasive breast carcinomas with
Ventana autostainer (Discovery Ultra, Ventana Medical
systems, Tuscon, AZ, USA). After peroxidase block
(Roche Diagnostics, 760–4840) (8 min), the sections
were incubated with anti-integrin α11 210F4B6A4
(0.29 μg/ml) (1 h RT), Omnimap anti-mouse HRP
(Roche Diagnostics, 760–4310) (16 min) and amplifica-
tion with Amp HQ kit (Roche Diagnostics, 760–052)
(20 min) and anti-HQ HRP (Roche Diagnostics,
760–4602) (16 min) following visualization with teal
(Roche Diagnostics, 760–247) (32 + 16 min). The sec-
tions were denaturated in CC2 (Ventana, 950–243)
(8 min 100 C), and incubated with anti-αSMA (Dako,
M0851) (1:100, 36 C 32 min), Ultramap-anti mouse
AP (Roche Diagnostics, 760–4312) (16 min) and
visualized with yellow (Roche Diagnostics, 760–239)
(44 min). After another denaturation with reaction
buffer (Ventana, 95–300) (95 C 20 min), the sec-
tions were incubated with anti-FVIII (Dako, A0088)
(1:1600, 1 h RT), Ultramap anti-rabbit HRP (Roche
Diagnostics, 760–4315) (12 min) and then purple
(Roche Diagnostics, 760–229) (20 min).
Double immunofluorescent staining with antibodies
against integrin α11 and cytokeratin-14 (CK14) was
done on 15 FFPE invasive breast carcinomas. After
antigen retrieval, the sections were incubated with
PBS/1% BSA/0.1% TritonX-100, followed by anti-
human integrin α11 210F4B6A4 (1.5 μg/ml) in
combination with anti-CK14 (Abcam, Cambridge,
United Kingdom, 119695) (1:700) (1 h RT), and then
Alexa Fluor® 594 goat anti-mouse IgG (AffiniPure,
Jackson ImmunoResearch, West Grove, PA, USA,
115-585-062) (1:700) and Alexa Fluor® 488 goat anti-
rabbit IgG (AffiniPure, 111-545-045) (1:700) (1 h
RT). Mounting was done with ProLong™ Gold Anti-
fade Mountant with DAPI (ThermoFisher, Waltham,
MA, USA, P36931) and results recorded using a Zeiss
Axioscope microscope equipped with Colibri 7 light
source, AxioCam 503 mono camera and Axiovision
software.
Evaluation of staining
Breast cancer sections were examined blinded for
patient characteristics and outcome by a senior breast
cancer pathologist, LAA, and HYHS. Of 520 stained
sections, 128 tumors were excluded from evaluation
because of inadequate tissue remaining after the anti-
gen retrieval procedure. Altogether 392 cases were
evaluated for integrin α11-positive staining by a
staining index (SI) score (0–9) which was obtained by
multiplying the score for intensity of staining (0 =
absent, 1 = weak, 2 = moderate, or 3 = strong) by the
score for percentage of fibrous stroma stained
(<10% = 1, 10–50% = 2, >50% = 3) [27]. Only posi-
tive staining in the tumor stroma was scored, and areas
with hemorrhage and necrosis were avoided. Intratumor
heterogeneity of stromal integrin α11 expression was
also noted.
As there is no pre-established cut-off value for
integrin α11, the distribution and frequency histograms
for SI were evaluated. As seen in supplementary mate-
rial, Figure S1, there was a clear binary distribution,
and the breast cancer cases were therefore separated
into integrin α11-low expression (SI 0–3 = 34%) and
integrin α11-high expression (SI 4–9 = 66%) by this
distribution, corresponding to a cut-off value at the
lower tertile.
Gene expression data sets
Gene expression microarray data generated by the
Molecular Taxonomy of Breast Cancer International
Consortium (METABRIC) were included for analyses
of ITGA11 mRNA expression across breast cancer
molecular subtypes and its relation to survival (discov-
ery and validation cohorts) [28]. Cases of the normal-
like molecular subtype were excluded, leaving n = 939
and n = 843 for analyses in the two cohorts. Two
ITGA11 probes were present in the METABRIC data.
The max probe expression value was selected for
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analyses [29]. Lower tertile was applied as cut-off,
corresponding to the cut-off level of the protein
staining.
Statistical analyses
Associations between categorical data were estimated
using the Pearson’s chi-square test and OR were com-
puted. Differences in integrin α11 protein and mRNA
expression across molecular subgroups were tested by
Kruskal–Wallis test. Results were accepted as statisti-
cally significant when p < 0.05 (two-sided). Univariate
survival data were analyzed by the Kaplan–Meier
method, with death from breast cancer as end-point
(time in months from diagnosis until death from breast
cancer), and the significance determined by the log-
rank test. Statistical analyses were performed using the
IBM SPSS Statistics for Windows, Version 25.0 (IBM
Corp, Armonk, NY, USA).
Results
Antibody specificity
As lack of reliable anti-human integrin α11 antibodies
has limited the investigation of integrin α11 on FFPE
tumor material, several novel monoclonal antibodies
specific for human integrin α11 chain were generated
and tested on FFPE tissues before use on the breast
cancer cohort. Hybridoma screening and antibody
characterization are demonstrated in [21,23], respec-
tively. In brief, clones specific to integrin α11 chain,
but not to other integrin subunits, such as integrin β1
and α2, were chosen. Furthermore, the specificity of
both 210F4B6A4 and D120.4 was validated by west-
ern blotting of cell lysates, and a polyclonal antibody
was used as control [24]. Both clone 210F4B6A4 and
D120.4 verified high expression of integrin α11 in
C2C12-α11 cells and no expression in C2C12-α2 cells
(Figure 1A). The human osteosarcoma cell line,
U2OS, showed low integrin α11 expression while the
human embryonic kidney cell line, HEK293, was neg-
ative for integrin α11 (Figure 1A). RT-qPCR con-
firmed the expression levels of integrin α11 in these
cell lines (Figure 1B).
The clones were tested on FFPE material, and it
became evident that high temperature was crucial to
unmask the antigen. Extensive testing of different pro-
tocols was done to find the most gentle antigen
retrieval protocol with high sensitivity. Several anti-
bodies showed distinct staining on FFPE tissue,
including 210F4B6A4 and D120.4. As 210F4B6A4
showed markedly strongest staining on FFPE tissue,
this antibody was used for further analyses. Staining
of FFPE cell pellets shows the validity of 210F4B6A4
on FFPE material (Figure 1C). Since other anti-
integrin α11 antibodies have been shown to lack speci-
ficity on FFPE tissue, a positive reagent control was
not applicable. Integrin α11 has recently been shown
to be highly upregulated in PDAC [21], and
corresponding cryo- and FFPE sections from the same
PDACs were used in the calibration of the IHC proto-
col, where the polyclonal integrin α11 antibody and
203E3 [21] were used as a control for the
cryosections. After optimizing the antigen retrieval
protocol on FFPE sections from cell pellets, PDACs
and invasive breast carcinomas, similar intensity and
expression pattern were seen in corresponding cryo-
and FFPE sections from five different PDACs (one
representative of five different tumors is shown in
Figure 1D). These sections were then used as biologi-
cal controls. To exclude run-to-run variability, serial
sections from five FFPE invasive breast carcinomas
were stained.
Integrin α11 is expressed in fibroblast-like cells in
breast cancer stroma
Positive staining was mainly seen as a fibrillar staining
pattern in the breast cancer stroma (Figure 2A–I and
see supplementary material, Figure S2A–I). Of note,
cells positive for integrin α11 were mainly spindle-
shaped, fibroblast-like cells, and the staining was often
markedly accentuated in direct proximity to the cancer
cells, indicating a ‘border’ between the epithelial com-
ponent and the ECM (Figure 2B,D,E,G–I and see sup-
plementary material, Figure S2A,B and D–F). In
addition to this fibrillar stromal positivity, membrane
staining of some of the breast myoepithelial cells was
also seen (Figure 3A–I).
Integrin α11 was expressed in spindle-shaped stro-
mal cells in 389 of 392 cases that were included for
evaluation (99%). The stromal staining was markedly
heterogeneous in 62% of the cases with an uneven dis-
tribution of integrin α11 expression (see supplemen-
tary material, Figure S3). Most of these heterogeneous
cases showed highest integrin α11 expression in the
central parts of the tumor with gradual loss of expres-
sion towards the invasive front (see supplementary
material, Figure S3). Integrin α11 expression was most
often weak in areas showing immune cell infiltration
(see supplementary material, Figure S2B), and fibrotic,
ECM-rich tissue was often positive for integrin α11
(see supplementary material, Figure S2C). No con-
vincing staining of tumor cells was observed, not even
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in invasive breast carcinomas with basal-like features
(see supplementary material, Figure S2G–I).
Integrin α11 co-localizes with αSMA in fibroblast-
like cells and with αSMA and cytokeratin-14 in
breast myoepithelium
To further characterize the expression of integrin
α11, we investigated its expression in relation to
αSMA, CK14, and FVIII in invasive breast carcino-
mas. Integrin α11 and αSMA expression showed a
clear co-localization in stromal spindle-shaped cells
(Figure 2D–F), but spindle-shaped cells only positive
for one of the markers were also observed (Figure 2F).
αSMA-positive, integrin α11-negative fibroblasts were
more prevalent than integrin α11-positive, αSMA-
negative fibroblasts. A minority of the vessels showed
weak integrin α11 expression.
Furthermore, integrin α11 expression was observed
in breast myoepithelial cells associated with ductal car-
cinoma in situ (DCIS), where it co-localized with
αSMA (Figure 3E–F) and CK14 (Figure 3G–I).
Integrin α11-positive myoepithelial cells were more
frequent and with higher intensity in DCIS
(Figure 3B–C,E–F, and G–I) compared to benign-
looking breast tissues where integrin α11 was mostly
negative (Figure 3D). Nevertheless, positive integrin
α11 staining was also observed in a small minority of
Figure 1. Validation of monoclonal antibodies against the integrin α11 subunit. Integrin α11-positive cell lines (C2C12-α11 and U2OS)
and integrin α11-negative cell lines (C2C12-α2 and HEK293) were used to validate the monoclonal antibodies. Western blots show only
expression of integrin α11 in cell lysates from integrin α11-positive cells using the monoclonal antibodies (mAbs) 210F4B6A4 and
D120.4 where a polyclonal antibody (pAb) was used as control (A). Comparison of mRNA expression of integrin α11 by RT-qPCR (B).
ITGA11 expression level is presented as the fold change in each cell line relative to C2C12-α11. Each column represents the average fold
change from three experiments, and error bar indicates standard deviation. Staining with 210F4B6A4 of FFPE cell pellets confirmed the
validity on FFPE material (C). Cases of pancreatic ductal adenocarcinoma stained with 210F4B6A4 showed similar stromal expression
pattern in corresponding cryosections and FFPE sections; images from one representative tumor are shown in (D). 203E3 was used as
control for the cryosections. Magnification: ×400.
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histologically benign ducts (Figure 3A). Interestingly,
Figure 2G–I and see supplementary material,
Figure S2D–F, demonstrate that the accentuated
integrin α11 expression in spindle-shaped cells near
tumor cells noted above probably represents tightly
associated fibroblasts, and not myoepithelial cells, as
these cells are negative for the myoepithelial
marker CK14.
Figure 2. Integrin α11 is expressed in fibroblast-like cells in breast cancer stroma. Integrin α11 expression in spindle-shaped cells in the
stroma of different invasive human breast carcinomas by IHC with 210F4B6A4. Different levels of integrin α11 expression are shown in
(A–C) (A; low intensity, B; medium strong intensity and C; strong intensity). (D–F) show triple staining of αSMA (yellow), integrin α11
(teal), and FVIII (purple) where co-localization of αSMA and integrin α11 appears green. Note that both integrin α11 and αSMA are
expressed in spindle-shaped stromal cells, but do not completely co-localize. Examples of double-positive spindle-shaped cells are mar-
ked with arrows, while one integrin α11-positive/αSMA-negative cell is marked with an arrowhead and one integrin α11-negative/
αSMA-positive cell marked with an asterisk. (G–I) show immunofluorescent double staining of integrin α11 (red), CK14 (green) and DAPI
(blue) of one invasive breast carcinoma. Note the strong integrin α11 expression in direct proximity to the tumor cells seen in (B), (D),
(E), and (J–L), and that this border is negative for CK14, indicating that this is not flattened integrin α11-positive breast myoepithelium.
Magnification: ×400 and ×200.
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High integrin α11 expression is associated with
features of aggressive breast cancer
Integrin α11 protein expression in stromal, spindle-
shaped cells was quantified by SI score (0–9),
obtained by multiplying the score for intensity of
staining by the score for percentage of fibrous
stroma stained. In total, 258 cases (66%) showed
high integrin α11 protein expression (SI 4–9),
whereas 134 cases (34%) showed low expression
(SI 0–3). While invasive carcinoma of no special
type, previously named invasive ductal carcinoma,
was associated with high integrin α11 protein
expression, invasive lobular carcinoma was associated
with low integrin α11 protein expression (Table 2).
Figure 3. Integrin α11 is expressed in a subgroup of breast myoepithelial cells. (A–C) show single staining of integrin α11 with weak
myoepithelial integrin α11 expression in benign-appearing ducts (A) and high myoepithelial integrin α11 expression in DCIS lesions
(B and C). (D–F) show triple staining of αSMA (yellow), integrin α11 (teal), and FVIII (purple) where co-localization of αSMA and integrin
α11 appears green; (D) shows terminal ducts and lobular units outside an invasive breast carcinoma with αSMA-positive, integrin
α11-negative myoepithelial cells, while (E–F) show co-localization of myoepithelial integrin α11 and αSMA in DCIS lesions. (G–I) shows
immunofluorescent double staining of integrin α11 (red), CK14 (green) and DAPI (blue) of one DCIS lesion with co-localization of
integrin α11 and CK14 in myoepithelial cells. IHC with 210F4B6A4. Magnification: ×400 and ×200.
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Furthermore, the expression of integrin α11 was sig-
nificantly higher in the aggressive HER2-positive
breast cancer subgroup both at protein and mRNA
level (Figures 4A and 5A,C).
Using the lower tertile as cut-off value (SI 0–3 =
34% versus SI 4–9 = 66%), high integrin α11 protein
expression was significantly associated with high histo-
logic grade (OR 5.0), estrogen receptor (ER) negativity
(OR 2.9), HER2 positivity (OR 2.7), triple-negative
phenotype (OR 2.5) and high tumor cell proliferation
by Ki-67 (OR 2.9) and mitotic count (OR 4.5)
(Table 2). Furthermore, high integrin α11 protein
expression was associated with the basal cell marker
CK5/6 (OR 3.3), but not with tumor diameter or lymph
node metastasis (Table 2).
In univariate survival analyses, neither integrin α11
protein expression nor integrin α11 mRNA expression
were significantly associated with breast cancer spe-
cific survival (Figures 4B and 5B,D). No significant
associations between integrin α11 expression and
breast cancer specific survival were found across dif-
ferent molecular breast cancer subgroups (see supple-
mentary material, Figures S4–S6), except that high
integrin α11 mRNA expression was found to be asso-
ciated with reduced survival in the Luminal B sub-
group in the METABRIC discovery cohort (see
Table 2. Associations between integrin α11 protein expression and clinico-pathological variables
α11 low (n = 134) α11 high (n = 258)
Variables n (%) n (%) OR (95% CI) P value*
Ductal carcinoma <0.001
No 37 (58) 27 (42) 1
Yes 97 (30) 231 (70) 3.3 (1.9–5.7)
Lobular carcinoma <0.001
Yes 27 (67) 13 (33) 1
No 107 (30) 245 (70) 4.8 (2.4–9.6)
Histologic grade <0.001
Grade 1–2 125 (40) 190 (60) 1
Grade 3 9 (12) 68 (88) 5.0 (2.4–10.3)
Tumor diameter 0.96
≤2 cm 98 (34) 188 (66) 1
>2 cm 36 (34) 70 (66) 1.0 (0.6–1.6)
Mitotic count†,‡ <0.001
Low count (≤5.5/mm2) 117 (43) 158 (57) 1
High count (>5.5/mm2) 16 (14) 98 (86) 4.5 (2.5–8.1)
Lymph node status 0.11
Negative 101 (37) 175 (63.4) 1
Positive 32 (28) 82 (72) 1.5 (0.9–2.4)
ER 0.001
Positive (≥10%) 121 (38) 197 (62) 1
Negative (<10%) 13 (18) 61 (82) 2.9 (1.5–5.5)
PR 0.53
Positive (≥10%) 91 (35) 167 (65) 1
Negative (<10%) 43 (32) 91 (68) 1.2 (0.7–1.8)
HER2§ 0.004
Negative 123 (37) 209 (63) 1
Positive 10 (18) 47 (82) 2.7 (1.3–5.7)
Ki67† <0.001
Low count (≤31.5%) 111 (41) 163 (59) 1
High count (>31.5%) 22 (19) 93 (81) 2.9 (1.7–4.9)
Triple-negative 0.022
No 126 (36) 223 (64) 1
Yes 8 (19) 35 (81) 2.5 (1.1–5.5)
CK 5/6 0.001
Negative (SI = 0) 124 (38) 207 (62) 1
Positive (SI > 0) 9 (16) 49 (84) 3.3 (1.5–6.9)
n, number of patients; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; CK 5/6, cytokeratin 5/6; SI: staining
index.
*Pearson chi-square.
†Cut-off value by upper quartile.
‡Mitotic count: number of mitoses per mm2.
§HER2-positive cases: HER2 IHC3+ and HER2 IHC2+ cases with a HER2/Chr17 ratio by silver in situ hybridization ≥ 2.0.
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Figure 4. Integrin α11 protein expression in human breast cancer. Integrin α11 protein expression across molecular subtypes of breast
cancer; data are presented as error-bars with 95% confidence interval of the mean, and P values by the Kruskal–Wallis test (A). Survival
curve by the Kaplan–Meier method for stromal integrin α11 expression; breast cancer specific survival in months, and P value by log-
rank test (B). For each category, the number of breast cancer deaths is given, followed by the total number of cases in each category.
Figure 5. Integrin α11 mRNA expression in human breast cancer in the METABRIC discovery and validation datasets. Integrin α11 mRNA
expression across molecular subtypes of breast cancer; data are presented as error-bars with 95% confidence interval of the mean, and
P values by the Kruskal–Wallis test (A,C). Survival curves by the Kaplan–Meier method for integrin α11 mRNA expression; breast cancer
specific survival in years, and P value by log rank test (B,D). For each category, the number of breast cancer deaths is given, followed by
the total number of cases in each category.
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supplementary material, Figure S5B), but this was not
validated at the protein level or in the METABRIC
validation cohort (see supplementary material, Fig-
ures S4B,C and S6B).
Discussion
Integrin α11β1 has been shown experimentally to stimu-
late tumor growth and progression [16,17,19,20], and to
be essential for fibroblast-matrix interactions [5,30].
Here, we present two new monoclonal mouse anti-
human integrin α11 antibodies, 210F4B6A4 and
D120.4, which bind to extracellular and intracellular
epitopes of the integrin α11 subunit, respectively. We
have established conditions for specific and reproduc-
ible integrin α11 staining of human FFPE tumor
material with 210F4B6A4. In a large breast cancer
cohort with long and complete follow-up, integrin
α11 was found to be expressed to varying degrees in
the stroma of 99% of the cases. In agreement with a
tumor-supportive effect of integrin α11β1, high
integrin α11 expression was associated with more
aggressive breast cancer phenotypes, even though
integrin α11 expression was not significantly corre-
lated to breast cancer specific survival.
Since existing anti-integrin α11 antibodies have
been shown to lack specificity on FFPE material in
our laboratory, we carefully developed and character-
ized novel antibodies. Since integrin α2 is one of the
most similar integrin chains [24], and is also found
expressed on fibroblasts [5], extra efforts were made
to exclude cross-reactivity against this integrin subunit.
The new monoclonal antibody 210F4B6A4 described
herein binds specifically to the integrin α11-chain
under several conditions, including western blotting
and immunostaining of FFPE material.
Although experimental studies have indicated a
tumor-stimulating effect of integrin α11β1 in different
preclinical models [16,17,19,20], and integrin α11β1
therefore has been suggested as a potential marker of a
pro-tumorigenic CAF subset, few investigations have
been performed on human tumor tissue due to lack of
a reliable antibody for use on FFPE material. In the
present study, investigating a breast cancer cohort of
392 patients, high integrin α11 expression in stromal
spindle-shaped cells was significantly associated with
high histologic grade, HER2 positivity, ER negativity,
triple-negative phenotype and expression of the basal
cell marker CK5/6, as well as high tumor cell prolifer-
ation by Ki-67 expression and mitotic count - all
markers of aggressive breast cancer phenotypes.
Notably, integrin α11 was expressed at higher protein
and mRNA levels in the aggressive HER2-positive
subtype of breast cancer. In addition to existing pre-
clinical data, these findings may indicate that integrin
α11-positive fibroblasts represent a subset of tumor-
supportive breast CAFs. However, high integrin α11
protein and mRNA expression was not associated with
survival. Similarly, Parajuli et al [31] did not find cor-
relations between stromal integrin α11 expression and
patient outcome in a series of head and neck cancers
using cryosections from the tumor center.
The cellular expression of different integrins is not
only subtype-specific, but is also dependent on tissue
type and context [4,32,33]. In the case of integrin
α11β1, the expression appears to be restricted to a
subgroup of fibroblasts and mesenchymal stem cells
[5], but the characterization of expression in human
tissue is so far limited. As there is a need to better
characterize CAF heterogeneity and to identify
markers that can help distinguish between tumor-
supportive and tumor-suppressive CAFs, several
IHC-based studies have used different markers to
identify tumor-supportive breast CAFs, such as
αSMA [34,35] and PDGFRβ [36,37]. In the present
study, we found that the integrin α11 subunit was
expressed in fibroblast-like cells in the breast tumor
stroma, and it predominantly co-localized with
αSMA. Similarly, αSMA and integrin α11 have pre-
viously been found to co-localize in the tumor stroma
of human head and neck cancers [31]. However, stro-
mal spindle-shaped cells with expression of either
integrin α11 or αSMA only were also observed in the
present study, which may represent different subpop-
ulations of CAFs (α11+/αSMA+, α11+/αSMA−, and
α11−/αSMA+) with potential functional differences
which should be investigated in future studies.
Normal mammary epithelium consists of an inner
luminal and a surrounding myoepithelial cell layer
[38]. Interestingly, integrin α11 was also found to
be expressed on myoepithelial cells surrounding
DCIS lesions, where it was found to co-localize
with αSMA and CK14, common markers of breast
myoepithelium. While αSMA and CK14 are general
myoepithelial markers, integrin α11 myoepithelial
expression appears to be more restricted, and was
mainly detected in in situ lesions, with absent or
very weak expression in benign-appearing lobules
and ducts. While the myoepithelium of benign ducts
is thought to act as an active tumor suppressor,
accumulating data indicate that DCIS-associated
myoepithelial cells show genetic, epigenetic and
molecular changes compared to myoepithelium in
benign tissue, and that their tumor-suppressive
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function may be lost with DCIS progression
[39,40]. As changes in myoepithelial cells have
been suggested to be an important contribution in
the transition from preinvasive to invasive cancer,
the molecular differences in preinvasive lesions may
represent markers for risk stratification or even tar-
gets for prevention of invasive breast cancer. Inter-
estingly, upregulation of another integrin, integrin
αvβ6, in breast myoepithelium, has been associated
with poor patient outcome and shown to promote
breast tumor proliferation experimentally [41].
Additional studies should address the role of myo-
epithelial integrin α11 expression in DCIS cohorts.
We observed fibrillar integrin α11 positivity which
was clearly strongest in direct proximity to the tumor
cells in the majority of breast cancer samples, and
dual staining with CK14 demonstrated that these cells
are probably not flattened myoepithelial cells. By the
methods used in this study, we cannot exclude that
such accentuated integrin α11 staining adjacent to
cancer cells may represent a subset of the tumor cell
population with a mesenchymal phenotype. Indeed,
integrin α11β1 has been suggested to be upregulated
during epithelial-to-mesenchymal transition, as it was
found to be part of a gene signature for some invad-
ing breast cancer cells in vitro [42], although this has
not been confirmed in other models or at the protein
level.
In conclusion, we have shown that the integrin
α11 subunit is expressed in fibroblasts-like cells in
invasive human breast carcinomas, and in myo-
epithelial cells in in situ lesions. High stromal
integrin α11 expression was associated with aggres-
sive breast cancer phenotypes, although integrin α11
mRNA and protein expression did not correlate with
breast cancer specific survival. It will be of further
interest to examine the expression of integrin α11 in
relation to other CAF markers, and to study the
functional role of integrin α11-expressing subpopu-
lations of breast CAFs.
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Integrin α11β1 is expressed in breast cancer stroma and associates with 
aggressive tumor phenotypes  
 







Figure S1. Frequency histogram for the integrin α11 staining index. Integrin α11 expression in 
spindle-shaped stromal cells was quantified by staining index score (0-9) which was obtained by 
multiplying the score for intensity of staining (0=absent, 1=weak, 2=moderate, or 3=strong) by the 








Figure S2. Integrin α11 expression in spindle-shaped cells in the stroma of invasive human breast 
carcinomas by IHC. A-C demonstrate single staining of integrin α11 (brown) while D-I shows 
immunofluorescent double staining of integrin α11 (red), CK14 (green) and DAPI (blue). Note the 
strong integrin α11 expression in direct proximity to the tumor cells seen in A, B and D-F. Areas with 
immune cell infiltration showed most often low integrin α11 expression (B), while fibrotic, extracellular 
matrix-rich tissue was mostly integrin α11-positive (C). In D-F, fibroblast-like cells positive for 
integrin α11 surrounding integrin α11-negative breast myoepithelium are seen. No convincing staining 
of breast tumor cells was seen - not even in tumors with basal-like features, as demonstrated by the 
breast carcinoma seen in G-I (tumor cells positive for CK14). IHC with 210F4B6A4. 400x and 200x.  
 
 
Figure S3. Intratumor heterogeneity of stromal integrin α11 expression in human invasive breast 
cancer. Images from three invasive human breast carcinomas demonstrate intratumor heterogenity of 
the expression of integrin α11 by IHC with 210F4B6A4. Note the gradient of integrin α11 expression 
with weaker expression towards the tumor periphery seen in tumor 3 (tumor periphery right part of the 
image). 200x and 100x.  
 
 
Figure S4. Survival curves across molecular subtypes according to stromal integrin α11 protein 
expression. Kaplan-Meier method, breast cancer specific survival in months, and p-values by log rank 
test. For each category, the number of breast cancer deaths is given, followed by the total number of 
cases in each category.  
 
Figure S5. Survival curves across molecular subtypes according to integrin α11 mRNA 
expression in the METABRIC discovery dataset. Kaplan-Meier method, breast cancer specific 
survival in years, and p-values by log rank test. For each category, the number of breast cancer deaths 
is given, followed by the total number of cases in each category.  
  
 
Figure S6. Survival curves across molecular subtypes according to integrin α11 mRNA 
expression in the METABRIC validation dataset. Kaplan-Meier method, breast cancer specific 
survival in years, and p-values by log rank test. For each category, the number of breast cancer deaths 
is given, followed by the total number of cases in each category. 
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